fact_key,concept,context_ref,value,unit_ref,decimals,numeric_value,period_type,period_start,period_end,entity_identifier,entity_scheme,period_key,label,original_label,statement_type,statement_role,period_instant,dim_us-gaap_StatementEquityComponentsAxis,dim_us-gaap_ConcentrationRiskByTypeAxis,dim_srt_MajorCustomersAxis,dim_srt_ProductOrServiceAxis,dim_us-gaap_TypeOfArrangementAxis,dim_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis,dim_us-gaap_FairValueByMeasurementFrequencyAxis,dim_us-gaap_FinancialInstrumentAxis,dim_us-gaap_FairValueByFairValueHierarchyLevelAxis,dim_srt_RangeAxis,dim_us-gaap_FairValueByAssetClassAxis,dim_srt_CounterpartyNameAxis,dim_us-gaap_OtherCommitmentsAxis,dim_us-gaap_IncomeStatementLocationAxis,dim_us-gaap_SubsidiarySaleOfStockAxis,dim_us-gaap_RestructuringCostAndReserveAxis,dim_us-gaap_SubsequentEventTypeAxis,ticker,filing_date,quarter,year,company_name
us-gaap_EarningsPerShareDiluted_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:EarningsPerShareDiluted,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0.00,Unit_Divide_USD_shares_37vC64oj8EqSLVdm8zK4dw,2,0.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Diluted (in dollars per share),Diluted (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareDiluted_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:EarningsPerShareDiluted,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-0.05,Unit_Divide_USD_shares_37vC64oj8EqSLVdm8zK4dw,2,-0.05,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Diluted (in dollars per share),Diluted (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:CommonStockSharesOutstanding,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,993699960,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,993699960.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityCentralIndexKey_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityCentralIndexKey,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0001621227,None,None,1621227.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Entity Central Index Key,Entity Central Index Key,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_CurrentFiscalYearEndDate_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:CurrentFiscalYearEndDate,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,--12-31,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Current Fiscal Year End Date,Current Fiscal Year End Date,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_DocumentFiscalYearFocus_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:DocumentFiscalYearFocus,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,2023,None,None,2023.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Document Fiscal Year Focus,Document Fiscal Year Focus,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_DocumentFiscalPeriodFocus_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:DocumentFiscalPeriodFocus,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,Q1,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Document Fiscal Period Focus,Document Fiscal Period Focus,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_AmendmentFlag_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:AmendmentFlag,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,false,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Amendment Flag,Amendment Flag,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityTaxIdentificationNumber_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityTaxIdentificationNumber,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,00-0000000,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Entity Tax Identification Number,Entity Tax Identification Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,987109890,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,987109890.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1036000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1036000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net profit/(loss) attributable to ordinary shareholders used for diluted profit/(loss) per share,Net profit/(loss) attributable to ordinary shareholders used for diluted profit/(loss) per share,Disclosures,http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-50265000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-50265000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net profit/(loss) attributable to ordinary shareholders used for diluted profit/(loss) per share,Net profit/(loss) attributable to ordinary shareholders used for diluted profit/(loss) per share,Disclosures,http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityFilerCategory_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityFilerCategory,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,Non-accelerated Filer,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Entity Filer Category,Entity Filer Category,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_DocumentType_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:DocumentType,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,10-Q,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Document Type,Document Type,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_DocumentQuarterlyReport_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:DocumentQuarterlyReport,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,true,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Document Quarterly Report,Document Quarterly Report,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_DocumentPeriodEndDate_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:DocumentPeriodEndDate,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,2023-03-31,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Document Period End Date,Document Period End Date,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_DocumentTransitionReport_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:DocumentTransitionReport,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,false,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Document Transition Report,Document Transition Report,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityFileNumber_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityFileNumber,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,001-37368,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Entity File Number,Entity File Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityRegistrantName_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityRegistrantName,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,ADAPTIMMUNE THERAPEUTICS PLC,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Entity Registrant Name,Entity Registrant Name,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityIncorporationStateCountryCode_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityIncorporationStateCountryCode,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,X0,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Entity Incorporation, State or Country Code","Entity Incorporation, State or Country Code",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityAddressAddressLine1_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityAddressAddressLine1,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"60 Jubilee Avenue, Milton Park",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Entity Address, Address Line One","Entity Address, Address Line One",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityAddressCityOrTown_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityAddressCityOrTown,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"Abingdon, Oxfordshire",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Entity Address, City or Town","Entity Address, City or Town",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityAddressPostalZipCode_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityAddressPostalZipCode,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,OX14 4RX,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Entity Address, Postal Zip Code","Entity Address, Postal Zip Code",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityAddressCountry_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityAddressCountry,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,GB,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Entity Address, Country","Entity Address, Country",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_CityAreaCode_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:CityAreaCode,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,44,None,None,44.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,City Area Code,City Area Code,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_LocalPhoneNumber_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:LocalPhoneNumber,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1235 430000,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Local Phone Number,Local Phone Number,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_Security12bTitle_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:Security12bTitle,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Title of 12(b) Security,Title of 12(b) Security,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_TradingSymbol_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:TradingSymbol,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,ADAP,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Trading Symbol,Trading Symbol,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_SecurityExchangeName_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:SecurityExchangeName,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,NASDAQ,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Security Exchange Name,Security Exchange Name,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityCurrentReportingStatus_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityCurrentReportingStatus,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,Yes,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Entity Current Reporting Status,Entity Current Reporting Status,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityInteractiveDataCurrent_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityInteractiveDataCurrent,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,Yes,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Entity Interactive Data Current,Entity Interactive Data Current,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntitySmallBusiness_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntitySmallBusiness,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,true,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Entity Small Business,Entity Small Business,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityEmergingGrowthCompany_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityEmergingGrowthCompany,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,false,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Entity Emerging Growth Company,Entity Emerging Growth Company,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityShellCompany_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,dei:EntityShellCompany,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,false,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Entity Shell Company,Entity Shell Company,CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
dei_EntityCommonStockSharesOutstanding_As_Of_5_10_2023_0pDxM6jQYkmrwz1Bitbxrw,dei:EntityCommonStockSharesOutstanding,As_Of_5_10_2023_0pDxM6jQYkmrwz1Bitbxrw,994213968,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,994213968.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-05-10,"Entity Common Stock, Shares Outstanding","Entity Common Stock, Shares Outstanding",CoverPage,http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation,2023-05-10,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,108033000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,108033000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,96572000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,96572000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Allowance for expected credit losses,Allowance for expected credit losses,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Allowance for expected credit losses,Allowance for expected credit losses,BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:AccountsReceivableNetCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,1715000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1715000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:AccountsReceivableNetCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,7435000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,7435000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseAndOtherAssetsCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:PrepaidExpenseAndOtherAssetsCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,46479000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,46479000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Other current assets and prepaid expenses,Other current assets and prepaid expenses,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseAndOtherAssetsCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:PrepaidExpenseAndOtherAssetsCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,43330000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,43330000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Other current assets and prepaid expenses,Other current assets and prepaid expenses,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AssetsCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:AssetsCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,213748000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,213748000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total current assets,Total current assets,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AssetsCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:AssetsCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,255370000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,255370000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total current assets,Total current assets,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:RestrictedCashAndCashEquivalentsNoncurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,1569000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1569000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Restricted cash,Restricted cash,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_OperatingLeaseRightOfUseAssetAccumulatedAmortization_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,adap:OperatingLeaseRightOfUseAssetAccumulatedAmortization,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,10296000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,10296000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Operating lease right-of-use assets, accumulated amortization","Operating lease right-of-use assets, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_OperatingLeaseRightOfUseAssetAccumulatedAmortization_Duration_1_1_2022_To_12_31_2022_tEKjnT8sNEST1WMUfr5Hbw,adap:OperatingLeaseRightOfUseAssetAccumulatedAmortization,Duration_1_1_2022_To_12_31_2022_tEKjnT8sNEST1WMUfr5Hbw,9470000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,9470000.0,duration,2022-01-01,2022-12-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-12-31,"Operating lease right-of-use assets, accumulated amortization","Operating lease right-of-use assets, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseRightOfUseAsset_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:OperatingLeaseRightOfUseAsset,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,17947000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,17947000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Operating lease right-of-use assets, net of accumulated amortization of $10,296 and $9,470","Operating lease right-of-use assets, net of accumulated amortization of $10,296 and $9,470",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseRightOfUseAsset_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:OperatingLeaseRightOfUseAsset,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,18019000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,18019000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Operating lease right-of-use assets, net of accumulated amortization of $10,296 and $9,470","Operating lease right-of-use assets, net of accumulated amortization of $10,296 and $9,470",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,38534000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,38534000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Property, plant and equipment, accumulated depreciation","Property, plant and equipment, accumulated depreciation",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,38588000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,38588000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Property, plant and equipment, accumulated depreciation","Property, plant and equipment, accumulated depreciation",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PropertyPlantAndEquipmentNet_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:PropertyPlantAndEquipmentNet,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,54365000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,54365000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Property, plant and equipment, net of accumulated depreciation of $38,534 and $38,588","Property, plant and equipment, net of accumulated depreciation of $38,534 and $38,588",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PropertyPlantAndEquipmentNet_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:PropertyPlantAndEquipmentNet,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,53516000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,53516000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Property, plant and equipment, net of accumulated depreciation of $38,534 and $38,588","Property, plant and equipment, net of accumulated depreciation of $38,534 and $38,588",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,4904000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4904000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Intangibles, accumulated amortization","Intangibles, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,4676000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4676000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Intangibles, accumulated amortization","Intangibles, accumulated amortization",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_IntangibleAssetsNetExcludingGoodwill_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:IntangibleAssetsNetExcludingGoodwill,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,443000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,443000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Intangible assets, net of accumulated amortization of $4,904 and $4,676","Intangible assets, net of accumulated amortization of $4,904 and $4,676",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_IntangibleAssetsNetExcludingGoodwill_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:IntangibleAssetsNetExcludingGoodwill,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,442000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,442000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Intangible assets, net of accumulated amortization of $4,904 and $4,676","Intangible assets, net of accumulated amortization of $4,904 and $4,676",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_Assets_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:Assets,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,288081000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,288081000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total assets,Total assets,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_Assets_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:Assets,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,328916000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,328916000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total assets,Total assets,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:AccountsPayableCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,5187000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,5187000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accounts payable,Accounts payable,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:AccountsPayableCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,4753000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4753000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accounts payable,Accounts payable,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:OperatingLeaseLiabilityCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,2842000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,2842000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Operating lease liabilities, current","Operating lease liabilities, current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:OperatingLeaseLiabilityCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,2728000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,2728000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Operating lease liabilities, current","Operating lease liabilities, current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:ContractWithCustomerLiabilityCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,22304000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,22304000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Deferred revenue, current","Deferred revenue, current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:ContractWithCustomerLiabilityCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,23520000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,23520000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Deferred revenue, current","Deferred revenue, current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:LiabilitiesCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,63631000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,63631000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total current liabilities,Total current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:LiabilitiesCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,64501000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,64501000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total current liabilities,Total current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityNoncurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:OperatingLeaseLiabilityNoncurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,19991000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,19991000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Operating lease liabilities, non-current","Operating lease liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiabilityNoncurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:OperatingLeaseLiabilityNoncurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,20349000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,20349000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Operating lease liabilities, non-current","Operating lease liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityNoncurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:ContractWithCustomerLiabilityNoncurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,119251000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,119251000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Deferred revenue, non-current","Deferred revenue, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityNoncurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:ContractWithCustomerLiabilityNoncurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,160892000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,160892000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Deferred revenue, non-current","Deferred revenue, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesNoncurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:OtherLiabilitiesNoncurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,1332000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1332000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Other liabilities, non-current","Other liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesNoncurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:OtherLiabilitiesNoncurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,1296000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1296000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Other liabilities, non-current","Other liabilities, non-current",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_Liabilities_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:Liabilities,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,204205000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,204205000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total liabilities,Total liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_Liabilities_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:Liabilities,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,247038000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,247038000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total liabilities,Total liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockParOrStatedValuePerShare_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:CommonStockParOrStatedValuePerShare,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,0.001,Unit_Divide_GBP_shares_jN3ALuX6gkefFXZocg5EOQ,3,0.001,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Common stock, par value","Common stock, par value",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockParOrStatedValuePerShare_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:CommonStockParOrStatedValuePerShare,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,0.001,Unit_Divide_GBP_shares_jN3ALuX6gkefFXZocg5EOQ,3,0.001,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Common stock, par value","Common stock, par value",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesAuthorized_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:CommonStockSharesAuthorized,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,1282773750,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,1282773750.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Common stock, shares authorized","Common stock, shares authorized",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesIssued_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:CommonStockSharesIssued,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,993699960,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,993699960.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Common stock, shares issued","Common stock, shares issued",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesAuthorized_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:CommonStockSharesAuthorized,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,1282773750,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,1282773750.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Common stock, shares authorized","Common stock, shares authorized",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesIssued_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:CommonStockSharesIssued,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,987109890,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,987109890.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Common stock, shares issued","Common stock, shares issued",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockValue_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:CommonStockValue,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,1407000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1407000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Common stock - Ordinary shares par value £0.001, 1,282,773,750 authorized and 993,699,960 issued and outstanding (2022: 1,282,773,750 authorized and 987,109,890 issued and outstanding)","Common stock - Ordinary shares par value £0.001, 1,282,773,750 authorized and 993,699,960 issued and outstanding (2022: 1,282,773,750 authorized and 987,109,890 issued and outstanding)",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockValue_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:CommonStockValue,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,1399000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1399000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Common stock - Ordinary shares par value £0.001, 1,282,773,750 authorized and 993,699,960 issued and outstanding (2022: 1,282,773,750 authorized and 987,109,890 issued and outstanding)","Common stock - Ordinary shares par value £0.001, 1,282,773,750 authorized and 993,699,960 issued and outstanding (2022: 1,282,773,750 authorized and 987,109,890 issued and outstanding)",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AdditionalPaidInCapital_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:AdditionalPaidInCapital,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,992520000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,992520000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Additional paid in capital,Additional paid in capital,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AdditionalPaidInCapital_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:AdditionalPaidInCapital,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,990656000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,990656000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Additional paid in capital,Additional paid in capital,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,-1785000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-1785000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,-875000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-875000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,-909302000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-909302000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesAndStockholdersEquity_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:LiabilitiesAndStockholdersEquity,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,288081000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,288081000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total liabilities and stockholders' equity,Total liabilities and stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LiabilitiesAndStockholdersEquity_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:LiabilitiesAndStockholdersEquity,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,328916000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,328916000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total liabilities and stockholders' equity,Total liabilities and stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ResearchAndDevelopmentExpense_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ResearchAndDevelopmentExpense,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,25548000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,25548000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Research and development,Research and development,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ResearchAndDevelopmentExpense_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:ResearchAndDevelopmentExpense,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,36752000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,36752000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Research and development,Research and development,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_GeneralAndAdministrativeExpense_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:GeneralAndAdministrativeExpense,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,20397000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,20397000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,General and administrative,General and administrative,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_GeneralAndAdministrativeExpense_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:GeneralAndAdministrativeExpense,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,16804000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,16804000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,General and administrative,General and administrative,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:CostsAndExpenses,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,-45945000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-45945000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CostsAndExpenses_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:CostsAndExpenses,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-53556000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-53556000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Total operating expenses,Total operating expenses,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:OperatingIncomeLoss,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1656000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1656000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Operating profit/(loss),Operating profit/(loss),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingIncomeLoss_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:OperatingIncomeLoss,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-49981000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-49981000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Operating profit/(loss),Operating profit/(loss),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,676000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,676000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_InterestIncomeDebtSecuritiesAvailableForSaleOperating_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:InterestIncomeDebtSecuritiesAvailableForSaleOperating,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,338000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,338000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Interest income,Interest income,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,-671000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-671000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Other (expense) income, net","Other (expense) income, net",IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherNonoperatingIncomeExpense_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:OtherNonoperatingIncomeExpense,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,12000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,12000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Other (expense) income, net","Other (expense) income, net",IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1661000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1661000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Profit/(loss) before income tax expense,Profit/(loss) before income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-49631000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-49631000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Profit/(loss) before income tax expense,Profit/(loss) before income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,-625000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-625000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_IncomeTaxExpenseBenefit_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:IncomeTaxExpenseBenefit,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-634000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-634000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Income tax expense,Income tax expense,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareBasic_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:EarningsPerShareBasic,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0.00,Unit_Divide_USD_shares_37vC64oj8EqSLVdm8zK4dw,2,0.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Basic (in dollars per share),Basic (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareBasic_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:EarningsPerShareBasic,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-0.05,Unit_Divide_USD_shares_37vC64oj8EqSLVdm8zK4dw,2,-0.05,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Basic (in dollars per share),Basic (in dollars per share),IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_0,us-gaap:NetIncomeLoss,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1036000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1036000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net profit/(loss) attributable to ordinary shareholders,Net profit/(loss) attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_1,us-gaap:NetIncomeLoss,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1036000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1036000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net profit/(loss) attributable to ordinary shareholders,Net profit/(loss) attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_0,us-gaap:NetIncomeLoss,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-50265000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-50265000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net profit/(loss) attributable to ordinary shareholders,Net profit/(loss) attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_1,us-gaap:NetIncomeLoss,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-50265000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-50265000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net profit/(loss) attributable to ordinary shareholders,Net profit/(loss) attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency translation adjustments, tax","Foreign currency translation adjustments, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency translation adjustments, tax","Foreign currency translation adjustments, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,-16908000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-16908000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,16792000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,16792000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,15526000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,15526000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-13808000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-13808000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,472000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,472000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-1155000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-1155000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNetOfTax_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ComprehensiveIncomeNetOfTax,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,126000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,126000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total comprehensive profit/(loss) for the period,Total comprehensive profit/(loss) for the period,ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNetOfTax_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:ComprehensiveIncomeNetOfTax,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-48436000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-48436000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Total comprehensive profit/(loss) for the period,Total comprehensive profit/(loss) for the period,ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaqkdS2kGU2gf_WB8GC-wg,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaqkdS2kGU2gf_WB8GC-wg,987109890,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,987109890.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaqkdS2kGU2gf_WB8GC-wg,us-gaap:StockholdersEquity,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SaqkdS2kGU2gf_WB8GC-wg,1399000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1399000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1luWR8aSTUSw2S5Ub_-PmQ,us-gaap:StockholdersEquity,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1luWR8aSTUSw2S5Ub_-PmQ,990656000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,990656000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J2YHUziygEarpdA5rNAp8g,us-gaap:StockholdersEquity,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J2YHUziygEarpdA5rNAp8g,-875000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-875000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aX4zW8LIPUSOhQm_WwwvXg,us-gaap:StockholdersEquity,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aX4zW8LIPUSOhQm_WwwvXg,-909302000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-909302000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw_0,us-gaap:StockholdersEquity,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,81878000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,81878000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw_1,us-gaap:StockholdersEquity,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,81878000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,81878000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_22bUrZDbVUqqvK_Et5eJtw,us-gaap:NetIncomeLoss,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_22bUrZDbVUqqvK_Et5eJtw,1036000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1036000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net profit/(loss) attributable to ordinary shareholders,Net profit/(loss) attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_2,us-gaap:NetIncomeLoss,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1036000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1036000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net profit/(loss) attributable to ordinary shareholders,Net profit/(loss) attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mKAc0vQ8ckuSvC9SYi_zVw,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mKAc0vQ8ckuSvC9SYi_zVw,-910000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-910000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Other comprehensive loss,Other comprehensive loss,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,-910000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-910000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Other comprehensive loss,Other comprehensive loss,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tLh0eQWzSUSu5XuwpmHg_w,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tLh0eQWzSUSu5XuwpmHg_w,6035574,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,6035574.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tLh0eQWzSUSu5XuwpmHg_w,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tLh0eQWzSUSu5XuwpmHg_w,7000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,7000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gne3bjOnbkq_u63xNf3WLw,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gne3bjOnbkq_u63xNf3WLw,1000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,8000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,8000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesNewIssues_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tLh0eQWzSUSu5XuwpmHg_w,us-gaap:StockIssuedDuringPeriodSharesNewIssues,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tLh0eQWzSUSu5XuwpmHg_w,554496,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,554496.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Issuance of shares upon completion of public offering, net of issuance costs (in shares)","Issuance of shares upon completion of public offering, net of issuance costs (in shares)",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tLh0eQWzSUSu5XuwpmHg_w,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tLh0eQWzSUSu5XuwpmHg_w,1000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Issuance of shares upon completion of public offering, net of issuance costs","Issuance of shares upon completion of public offering, net of issuance costs",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gne3bjOnbkq_u63xNf3WLw,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gne3bjOnbkq_u63xNf3WLw,187000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,187000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Issuance of shares upon completion of public offering, net of issuance costs","Issuance of shares upon completion of public offering, net of issuance costs",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueNewIssues_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:StockIssuedDuringPeriodValueNewIssues,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,188000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,188000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Issuance of shares upon completion of public offering, net of issuance costs","Issuance of shares upon completion of public offering, net of issuance costs",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gne3bjOnbkq_u63xNf3WLw,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Gne3bjOnbkq_u63xNf3WLw,1676000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1676000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1676000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1676000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aTFvGrsHDEapvAi-ezO-RA,us-gaap:CommonStockSharesOutstanding,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aTFvGrsHDEapvAi-ezO-RA,993699960,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,993699960.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2023-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aTFvGrsHDEapvAi-ezO-RA,us-gaap:StockholdersEquity,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aTFvGrsHDEapvAi-ezO-RA,1407000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1407000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oBuFYVJdjkWnCPkAP0jbGA,us-gaap:StockholdersEquity,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oBuFYVJdjkWnCPkAP0jbGA,992520000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,992520000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ApSY2QoC7EO4lVj1RfgwHw,us-gaap:StockholdersEquity,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ApSY2QoC7EO4lVj1RfgwHw,-1785000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-1785000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EEpx-ePiz0uZQvcd76VdAQ,us-gaap:StockholdersEquity,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_EEpx-ePiz0uZQvcd76VdAQ,-908266000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-908266000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_0,us-gaap:StockholdersEquity,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,83876000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,83876000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_1,us-gaap:StockholdersEquity,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,83876000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,83876000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QDh-HcMSWUGUx_Sjwe0NLg,us-gaap:CommonStockSharesOutstanding,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QDh-HcMSWUGUx_Sjwe0NLg,937547934,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,937547934.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2021-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QDh-HcMSWUGUx_Sjwe0NLg,us-gaap:StockholdersEquity,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QDh-HcMSWUGUx_Sjwe0NLg,1337000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1337000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_R5aTsCnut0ypD9YzPTTl5Q,us-gaap:StockholdersEquity,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_R5aTsCnut0ypD9YzPTTl5Q,959611000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,959611000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Hhp_QmUh00-e-76WTpFNzg,us-gaap:StockholdersEquity,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Hhp_QmUh00-e-76WTpFNzg,-11142000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-11142000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_k0TaeOmLX0GJh3xkeN-SGg,us-gaap:StockholdersEquity,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_k0TaeOmLX0GJh3xkeN-SGg,-743846000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-743846000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_12_31_2021_u14gYJY6y02wSqjoWLKn3w,us-gaap:StockholdersEquity,As_Of_12_31_2021_u14gYJY6y02wSqjoWLKn3w,205960000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,205960000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pc1x_OKDtkibwnKytNjrUg,us-gaap:NetIncomeLoss,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pc1x_OKDtkibwnKytNjrUg,-50265000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-50265000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net profit/(loss) attributable to ordinary shareholders,Net profit/(loss) attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_2,us-gaap:NetIncomeLoss,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-50265000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-50265000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net profit/(loss) attributable to ordinary shareholders,Net profit/(loss) attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SMQX_0CZtUe-prctzaAqMA,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SMQX_0CZtUe-prctzaAqMA,1829000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1829000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Other comprehensive loss,Other comprehensive loss,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,1829000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1829000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Other comprehensive loss,Other comprehensive loss,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8cMKg1wUFEONARfIXYkiGQ,us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8cMKg1wUFEONARfIXYkiGQ,3318072,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,3318072.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Issuance of shares upon exercise of stock options (in shares),Issuance of shares upon exercise of stock options (in shares),StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8cMKg1wUFEONARfIXYkiGQ,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8cMKg1wUFEONARfIXYkiGQ,5000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,5000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMBni0Ljbk2KYTwqMXO8Wg,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMBni0Ljbk2KYTwqMXO8Wg,30000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,30000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,35000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,35000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Issuance of shares upon exercise of stock options,Issuance of shares upon exercise of stock options,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMBni0Ljbk2KYTwqMXO8Wg,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GMBni0Ljbk2KYTwqMXO8Wg,5586000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,5586000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,5586000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,5586000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Share-based compensation expense,Share-based compensation expense,StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommonStockSharesOutstanding_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7FNARF38O0aVavI83s03Uw,us-gaap:CommonStockSharesOutstanding,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7FNARF38O0aVavI83s03Uw,940866006,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,940866006.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,"Common stock, shares outstanding","Common stock, shares outstanding",BalanceSheetParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical,2022-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7FNARF38O0aVavI83s03Uw,us-gaap:StockholdersEquity,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7FNARF38O0aVavI83s03Uw,1342000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1342000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:CommonStockMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iuPKW-cFQUu29tQIbWd05A,us-gaap:StockholdersEquity,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iuPKW-cFQUu29tQIbWd05A,965227000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,965227000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:AdditionalPaidInCapitalMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1jhlfm1OyUiRHSEm4lUGpQ,us-gaap:StockholdersEquity,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1jhlfm1OyUiRHSEm4lUGpQ,-9313000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-9313000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IlvJg7kN1kKmJGbhFN8XCQ,us-gaap:StockholdersEquity,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IlvJg7kN1kKmJGbhFN8XCQ,-794111000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-794111000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:RetainedEarningsMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquity_As_Of_3_31_2022_wzEb70mnG063uVdzeBzGKw,us-gaap:StockholdersEquity,As_Of_3_31_2022_wzEb70mnG063uVdzeBzGKw,163145000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,163145000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Total stockholders' equity,Total stockholders' equity,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ProfitLoss_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ProfitLoss,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1036000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1036000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net profit/(loss),Net profit/(loss),CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ProfitLoss_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:ProfitLoss,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-50265000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-50265000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net profit/(loss),Net profit/(loss),CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_Depreciation_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:Depreciation,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1659000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1659000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Depreciation,Depreciation,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_Depreciation_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:Depreciation,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,1386000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1386000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Depreciation,Depreciation,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentForAmortization_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:AdjustmentForAmortization,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,186000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,186000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Amortization,Amortization,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AdjustmentForAmortization_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:AdjustmentForAmortization,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,209000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,209000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Amortization,Amortization,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensation_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ShareBasedCompensation,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1676000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1676000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Share-based compensation expense,Share-based compensation expense,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensation_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:ShareBasedCompensation,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,5586000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,5586000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Share-based compensation expense,Share-based compensation expense,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyTransactionGainLossUnrealized_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ForeignCurrencyTransactionGainLossUnrealized,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,563000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,563000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Unrealized foreign exchange losses/(gains),Unrealized foreign exchange losses/(gains),CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyTransactionGainLossUnrealized_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:ForeignCurrencyTransactionGainLossUnrealized,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-244000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-244000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Unrealized foreign exchange losses/(gains),Unrealized foreign exchange losses/(gains),CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_AmortizationAccretionOfMarketableSecurities_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,adap:AmortizationAccretionOfMarketableSecurities,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,112000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,112000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Amortization on available-for-sale debt securities,Amortization on available-for-sale debt securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_AmortizationAccretionOfMarketableSecurities_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,adap:AmortizationAccretionOfMarketableSecurities,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,999000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,999000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Amortization on available-for-sale debt securities,Amortization on available-for-sale debt securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherOperatingActivitiesCashFlowStatement_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:OtherOperatingActivitiesCashFlowStatement,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,134000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,134000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Other,Other,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherOperatingActivitiesCashFlowStatement_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:OtherOperatingActivitiesCashFlowStatement,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,220000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,220000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Other,Other,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInCurrentAssets_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,adap:IncreaseDecreaseInCurrentAssets,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,3683000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,3683000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Decrease/(increase) in receivables and other operating assets,Decrease/(increase) in receivables and other operating assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInCurrentAssets_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,adap:IncreaseDecreaseInCurrentAssets,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-10759000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-10759000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Decrease/(increase) in receivables and other operating assets,Decrease/(increase) in receivables and other operating assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,21000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,21000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Increase in payables and other current liabilities,Increase in payables and other current liabilities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,964000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,964000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Increase in payables and other current liabilities,Increase in payables and other current liabilities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInContractWithCustomerLiability_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:IncreaseDecreaseInContractWithCustomerLiability,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,-46353000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-46353000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Decrease in deferred revenue,Decrease in deferred revenue,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_IncreaseDecreaseInContractWithCustomerLiability_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:IncreaseDecreaseInContractWithCustomerLiability,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-2497000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-2497000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Decrease in deferred revenue,Decrease in deferred revenue,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInOperatingActivities_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:NetCashProvidedByUsedInOperatingActivities,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,-37283000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-37283000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net cash used in operating activities,Net cash used in operating activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInOperatingActivities_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:NetCashProvidedByUsedInOperatingActivities,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-54401000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-54401000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net cash used in operating activities,Net cash used in operating activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:PaymentsToAcquirePropertyPlantAndEquipment,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,-2349000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-2349000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Acquisition of property, plant and equipment","Acquisition of property, plant and equipment",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:PaymentsToAcquirePropertyPlantAndEquipment,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-7114000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-7114000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Acquisition of property, plant and equipment","Acquisition of property, plant and equipment",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquireIntangibleAssets_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:PaymentsToAcquireIntangibleAssets,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,-173000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-173000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Acquisition of intangibles assets,Acquisition of intangibles assets,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,50863000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,50863000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Maturity or redemption of marketable securities,Maturity or redemption of marketable securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,44536000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,44536000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Maturity or redemption of marketable securities,Maturity or redemption of marketable securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PaymentsToAcquireMarketableSecurities_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:PaymentsToAcquireMarketableSecurities,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-42197000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-42197000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Investment in marketable securities,Investment in marketable securities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInInvestingActivities_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:NetCashProvidedByUsedInInvestingActivities,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,48341000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,48341000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net cash provided by/(used in) investing activities,Net cash provided by/(used in) investing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInInvestingActivities_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:NetCashProvidedByUsedInInvestingActivities,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-4775000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-4775000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net cash provided by/(used in) investing activities,Net cash provided by/(used in) investing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOfCommonStock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ProceedsFromIssuanceOfCommonStock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,188000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,188000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Proceeds from issuance of common stock from offerings, net of commissions and issuance costs","Proceeds from issuance of common stock from offerings, net of commissions and issuance costs",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromStockOptionsExercised_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ProceedsFromStockOptionsExercised,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,8000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,8000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Proceeds from exercise of stock options,Proceeds from exercise of stock options,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromStockOptionsExercised_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:ProceedsFromStockOptionsExercised,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,35000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,35000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Proceeds from exercise of stock options,Proceeds from exercise of stock options,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInFinancingActivities_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:NetCashProvidedByUsedInFinancingActivities,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,196000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,196000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net cash provided by financing activities,Net cash provided by financing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetCashProvidedByUsedInFinancingActivities_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:NetCashProvidedByUsedInFinancingActivities,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,35000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,35000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net cash provided by financing activities,Net cash provided by financing activities,CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,588000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,588000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Effect of currency exchange rate changes on cash, cash equivalents and restricted cash","Effect of currency exchange rate changes on cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-1270000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-1270000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Effect of currency exchange rate changes on cash, cash equivalents and restricted cash","Effect of currency exchange rate changes on cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,11842000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,11842000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Net increase/(decrease) in cash, cash equivalents and restricted cash","Net increase/(decrease) in cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-60411000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-60411000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Net increase/(decrease) in cash, cash equivalents and restricted cash","Net increase/(decrease) in cash, cash equivalents and restricted cash",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,109602000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,109602000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_12_31_2021_u14gYJY6y02wSqjoWLKn3w,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_12_31_2021_u14gYJY6y02wSqjoWLKn3w,151666000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,151666000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,2021-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,121444000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,121444000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_As_Of_3_31_2022_wzEb70mnG063uVdzeBzGKw,us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,As_Of_3_31_2022_wzEb70mnG063uVdzeBzGKw,91255000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,91255000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,"Cash, cash equivalents and restricted cash at end of period","Cash, cash equivalents and restricted cash at end of period",CashFlowStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows,2022-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NatureOfOperations_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:NatureOfOperations,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 1 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> General</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to people with cancer. We are a leader in the development of T-cell therapies for solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage of clinical development including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its cell therapies, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of its cell therapies, the need to develop a reliable commercial manufacturing process, the need to commercialize any cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its cell therapies, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of $908,266,000 as of March 31, 2023.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,General,General,Disclosures,http://www.adaptimmune.com/role/DisclosureGeneral,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_0,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,-908266000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-908266000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RetainedEarningsAccumulatedDeficit_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_1,us-gaap:RetainedEarningsAccumulatedDeficit,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,-908266000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-908266000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accumulated deficit,Accumulated deficit,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 2 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Summary of Significant Accounting Policies </b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(a)          Basis of presentation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 6, 2023 (the “Annual Report”). The balance sheet as of December 31, 2022 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(b)          Use of estimates in interim financial statements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(c)          Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(d</b><b style=""font-weight:bold;"">)          Significant concentrations of credit risk</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company held cash and cash equivalents of $119,866,000, marketable securities of $45,688,000 and restricted cash of $1,578,000 as of March 31, 2023. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company had two customers during the three months ended March 31, 2023, which are Genentech and Astellas. There were accounts receivable of $1,715,000 as of March 31, 2023 and $7,435,000 as of December 31, 2022. The Company has been transacting with Genentech since 2021 and Astellas since 2020, during which time no credit losses have been recognized. As of March 31, 2023, no allowance for expected credit losses is recognised on the basis that the possibility of credit losses arising on its receivables as of March 31, 2023 is considered to be remote. As of March 31, 2023 there are no receivables, either accrued or billed, due from Astellas that are no longer recoverable following the termination of the Astellas Collaboration Agreement.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Management analyses current and past due accounts and determines if an allowance for credit losses is required based on collection experience, credit worthiness of customers and other relevant information. The process of estimating the uncollectible accounts involves assumptions and judgments and the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company does not hold cash deposits or securities with Silicon Valley Bank.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;white-space:pre-wrap;"">(e)          New accounting pronouncements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">Adopted in the current period</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Measurement of credit losses on financial instruments</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">In June 2016, the FASB issued ASU 2016-13 - Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. There was no material impact from the adoption of the guidance on the Company’s Consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""/>In October 2021, the FASB issued ASU 2021-08 – Business Combinations (Topic 805)- Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in and inconsistency related to the following: (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU resolve this inconsistency by requiring that an entity (acquirer) recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, in contrast to current GAAP which requires that assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities, are measured at fair value as of the acquisition date. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Adoption of the new standard had no impact on the Company’s Consolidated financial statements upon transition.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:28.35pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Summary of Significant Accounting Policies,Summary of Significant Accounting Policies,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_BasisOfAccountingPolicyPolicyTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:BasisOfAccountingPolicyPolicyTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(a)          Basis of presentation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The condensed consolidated financial statements of Adaptimmune Therapeutics plc and its subsidiaries and other financial information included in this Quarterly Report are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in U.S. dollars. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated on consolidation.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 6, 2023 (the “Annual Report”). The balance sheet as of December 31, 2022 was derived from audited consolidated financial statements included in the Company’s Annual Report but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are described in Note 2 to those consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period. The interim results are not necessarily indicative of results to be expected for the full year.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Basis of presentation,Basis of presentation,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_UseOfEstimates_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:UseOfEstimates,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(b)          Use of estimates in interim financial statements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The preparation of interim financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the interim financial statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are made in various areas, including in relation to valuation allowances relating to deferred tax assets, revenue recognition, and estimation of the incremental borrowing rate for operating leases. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Use of estimates in interim financial statements,Use of estimates in interim financial statements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_FairValueMeasurementPolicyPolicyTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:FairValueMeasurementPolicyPolicyTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(c)          Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The hierarchy defines three levels of valuation inputs:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 1 - Quoted prices in active markets for identical assets or liabilities</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Level 3 - Unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The carrying amounts of the Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The fair value of marketable securities, which are measured at fair value on a recurring basis is detailed in Note 6, Fair value measurements.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Fair value measurements,Fair value measurements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ConcentrationRiskCreditRisk_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ConcentrationRiskCreditRisk,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">(d</b><b style=""font-weight:bold;"">)          Significant concentrations of credit risk</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company held cash and cash equivalents of $119,866,000, marketable securities of $45,688,000 and restricted cash of $1,578,000 as of March 31, 2023. The cash and cash equivalents and restricted cash are held with multiple banks and the Company monitors the credit rating of those banks. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation in the United States and the U.K. Government Financial Services Compensation Scheme in the United Kingdom. The Company’s investment policy limits investments to certain types of instruments, such as money market instruments, corporate debt securities and commercial paper, places restrictions on maturities and concentration by type and issuer and specifies the minimum credit ratings for all investments and the average credit quality of the portfolio.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company had two customers during the three months ended March 31, 2023, which are Genentech and Astellas. There were accounts receivable of $1,715,000 as of March 31, 2023 and $7,435,000 as of December 31, 2022. The Company has been transacting with Genentech since 2021 and Astellas since 2020, during which time no credit losses have been recognized. As of March 31, 2023, no allowance for expected credit losses is recognised on the basis that the possibility of credit losses arising on its receivables as of March 31, 2023 is considered to be remote. As of March 31, 2023 there are no receivables, either accrued or billed, due from Astellas that are no longer recoverable following the termination of the Astellas Collaboration Agreement.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Management analyses current and past due accounts and determines if an allowance for credit losses is required based on collection experience, credit worthiness of customers and other relevant information. The process of estimating the uncollectible accounts involves assumptions and judgments and the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company does not hold cash deposits or securities with Silicon Valley Bank.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Significant concentrations of credit risk,Significant concentrations of credit risk,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_0,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,119866000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,119866000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CashAndCashEquivalentsAtCarryingValue_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_1,us-gaap:CashAndCashEquivalentsAtCarryingValue,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,119866000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,119866000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Cash and cash equivalents,Cash and cash equivalents,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_0,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,45688000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,45688000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_1,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,45688000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,45688000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_0,us-gaap:RestrictedCashAndCashEquivalentsNoncurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,1578000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1578000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Restricted cash,Restricted cash,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_1,us-gaap:RestrictedCashAndCashEquivalentsNoncurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,1578000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,1578000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Restricted cash,Restricted cash,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_NumberOfCustomers_As_Of_3_31_2023_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gXW6Rkv4vEa7p1gUSKDB4g,adap:NumberOfCustomers,As_Of_3_31_2023_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gXW6Rkv4vEa7p1gUSKDB4g,2,Unit_Standard_customer_CIUN5CHyNEGIDD-YVePVTg,INF,2.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Number of customers,Number of customers,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAccountsReceivableDetails,2023-03-31,None,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_3_31_2023_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gXW6Rkv4vEa7p1gUSKDB4g,us-gaap:AccountsReceivableNetCurrent,As_Of_3_31_2023_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_gXW6Rkv4vEa7p1gUSKDB4g,1715000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,1715000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_12_31_2022_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_o4UtOLbvU0WnOG61XbV-Ig,us-gaap:AccountsReceivableNetCurrent,As_Of_12_31_2022_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_o4UtOLbvU0WnOG61XbV-Ig,7435000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,7435000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,us-gaap:CustomerConcentrationRiskMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccountsReceivableNetCurrent_As_Of_3_31_2023_srt_MajorCustomersAxis_adap_AstellasPharmaInc.Member_oU5G-V33hEmfO-7QCVefvw,us-gaap:AccountsReceivableNetCurrent,As_Of_3_31_2023_srt_MajorCustomersAxis_adap_AstellasPharmaInc.Member_oU5G-V33hEmfO-7QCVefvw,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Accounts receivable, net of allowance for expected credit losses of $0 and $0","Accounts receivable, net of allowance for expected credit losses of $0 and $0",BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,adap:AstellasPharmaInc.Member,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;white-space:pre-wrap;"">(e)          New accounting pronouncements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">Adopted in the current period</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Measurement of credit losses on financial instruments</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">In June 2016, the FASB issued ASU 2016-13 - Financial Instruments - Credit losses, which replaces the incurred loss impairment methodology for financial instruments in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The guidance must be adopted using a modified-retrospective approach and a prospective transition approach is required for debt securities for which an other-than-temporary impairment had been recognized before the effective date. There was no material impact from the adoption of the guidance on the Company’s Consolidated financial statements.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""/>In October 2021, the FASB issued ASU 2021-08 – Business Combinations (Topic 805)- Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in and inconsistency related to the following: (1) recognition of an acquired contract liability and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. The amendments in this ASU resolve this inconsistency by requiring that an entity (acquirer) recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606, in contrast to current GAAP which requires that assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities, are measured at fair value as of the acquisition date. The Company adopted the guidance in the fiscal year beginning January 1, 2023. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Adoption of the new standard had no impact on the Company’s Consolidated financial statements upon transition.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,New accounting pronouncements,New accounting pronouncements,Disclosures,http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:RevenueFromContractWithCustomerTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 3 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Revenue</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt 0pt 12pt 0pt;"">The Company had two revenue-generating contracts with customers in the three months ended March 31, 2023, compared to three in the three months ended March 31, 2022: a collaboration agreement with Astellas that was terminated as of March 6, 2023 and a strategic collaboration and license agreement with Genentech. A further collaboration and license agreement with GSK was terminated in 2022.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt;"">Revenue comprises the following categories (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:45.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:45.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:19.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:19.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Development revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 47,601</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,575</p></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 47,601</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,575</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">Deferred revenue decreased by $42,857,000 from $184,412,000 at December 31, 2022 to $141,555,000 at March 31, 2023 primarily due to revenue recognized during the quarter but was partially offset by a $3,368,000 increase caused by the change in the exchange rate between pound sterling and the U.S. dollar from £1.00 to $1.21 at December 31, 2022 to £1.00 to $1.24 at March 31, 2023. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">As of December 31, 2022, there was deferred revenue of $184,412,000 of which $46,784,000 was recognized as revenue in the three months ended March 31, 2023</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements as of March 31, 2023 was $283,005,000. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The Genentech Collaboration and License Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the Genentech agreement as of March 31, 2023 was $283,005,000. Of this amount $174,008,000 is allocated to the research services and rights granted for the initial ‘off-the-shelf’ collaboration targets, $89,843,000 is allocated to the research services and rights granted for the personalized therapies, $12,929,000 is allocated to the material rights to designate the additional ‘off-the-shelf’ collaboration targets, $4,980,000 is allocated to the material right for the first option to extend the research term and $1,245,000 is allocated to the material right for the option to extend the research term a second time. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company expects to satisfy the performance obligations relating to the initial ‘off-the-shelf’ collaboration targets and the personalized therapies as development progresses and recognizes revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company expects to satisfy the performance obligations relating to the material rights to designate additional ‘off-the-shelf’ collaboration targets from the point that the options are exercised and then as development progresses, in line with the initial ‘off-the-shelf’ collaboration targets, or at the point in time that the rights expire. The Company expects to satisfy the performance obligations relating to the material rights to extend the </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"">research term from the point that the options are exercised and then over the period of the extension, or at the point in time that the rights expire.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The Astellas Collaboration Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company and Universal Cells mutually agreed to terminate the Astellas Collaboration Agreement as of March 6, 2023 (the “Termination Date”). In connection with the termination, all licenses and sublicenses granted to either party pursuant to the Collaboration Agreement ceased as of the Termination Date. There were no termination penalties in connection with the termination, however the Company is still entitled to receive reimbursement for research and development work performed up to and including a period of 30 days after the Termination Date.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company originally satisfied the performance obligations relating to the three co-development targets as development progresses and recognized revenue based on an estimate of the percentage of completion of the project determined based on the costs incurred on the project as a percentage of the total expected costs. The Company originally determined that the performance obligations relating to the two independent Astellas targets would be recognized at a point-in-time, upon commencement of the licenses in the event of nomination of the target, since they were right-to-use licenses.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The termination was accounted for as a contract modification on a cumulative catch-up basis. No performance obligations were identified as a result of the modification as there were no further goods or services to be provided by the Company and the modification resulted in the remaining unsatisfied and partially satisfied performance obligations under the collaboration becoming fully satisfied. The aggregate transaction price of the contract modification was $42,365,000 which included the remaining deferred income that had not been recognized as revenue as of the date of the modification and variable consideration from the remaining reimbursement income to be billed under the collaboration at the end of the 30 day period after the Effective Date. The transaction price of the modification was recognized in full in March 2023 and there is no remaining transaction price allocated to performance obligations that are unsatisfied or partially satisfied under, and no remaining deferred income relating to, the agreement as of March 31, 2023.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">The GSK Collaboration and License Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The GSK Collaboration and License Agreement consisted of multiple performance obligations, including the development of a third target, which was the only performance obligation for which revenue was recognised in 2022. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""white-space:pre-wrap;"">The collaboration was terminated by GSK in October 2022 (effective December 23, 2022).  A further amendment to the collaboration agreement was entered into on December 19, 2022 for the deletion of certain provisions relating to GSK’s post termination manufacturing and supply obligations and payment of </span>£5,000,000 by GSK to Adaptimmune. The aggregate transaction price of the contract modification was $6,500,000, which was recognized as revenue on the date of the modification. No revenue was recognized in relation to the GSK Collaboration and License Agreement in 2023.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">A further Termination and Transfer Agreement was entered into on April 6, 2023. As this occurred after March 31, 2023, there was no impact on the Consolidated financial statements in the three months ended March 31, 2023, see Note 15 for further details.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Revenue,Revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenue,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_NumberOfContractsWithCustomer_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,adap:NumberOfContractsWithCustomer,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,2,Unit_Standard_contract_WROMA4JfzU2hDmKDH0XLrQ,INF,2.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Number of contracts with customers,Number of contracts with customers,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_NumberOfContractsWithCustomer_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,adap:NumberOfContractsWithCustomer,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,3,Unit_Standard_contract_WROMA4JfzU2hDmKDH0XLrQ,INF,3.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Number of contracts with customers,Number of contracts with customers,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DisaggregationOfRevenueTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:DisaggregationOfRevenueTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:33.75pt;margin:0pt;"">Revenue comprises the following categories (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:45.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:45.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:19.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:19.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Development revenue</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 47,601</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,575</p></td></tr><tr><td style=""vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 47,601</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:17.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,575</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Summary of revenue categories,Summary of revenue categories,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_RrRUjwRNyEKy072XJeP9tw,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2023_To_3_31_2023_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_RrRUjwRNyEKy072XJeP9tw,47601000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,47601000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_GDGiXhOPFEu0ReIAoIY5dw,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2022_To_3_31_2022_srt_ProductOrServiceAxis_adap_DevelopmentRevenueMember_GDGiXhOPFEu0ReIAoIY5dw,3575000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,3575000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,adap:DevelopmentRevenueMember,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,47601000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,47601000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,47601000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,47601000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_0,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,3575000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,3575000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_1,us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,3575000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,3575000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Revenue,Revenue,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_DecreaseInContractWithCustomerLiability_Duration_1_1_2022_To_12_31_2022_tEKjnT8sNEST1WMUfr5Hbw,adap:DecreaseInContractWithCustomerLiability,Duration_1_1_2022_To_12_31_2022_tEKjnT8sNEST1WMUfr5Hbw,42857000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,42857000.0,duration,2022-01-01,2022-12-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-12-31,Deferred revenue decrease,Deferred revenue decrease,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiability_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:ContractWithCustomerLiability,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,141555000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,141555000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Deferred revenue,Deferred revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_IncreaseDecreaseInContractWithCustomerChangeInExchangeRateLiability_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,adap:IncreaseDecreaseInContractWithCustomerChangeInExchangeRateLiability,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,3368000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,3368000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Amount of decrease in deferred income caused by the change in the exchange rate,Amount of decrease in deferred income caused by the change in the exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyExchangeRateTranslation1_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:ForeignCurrencyExchangeRateTranslation1,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,1.21,Unit_Standard_pure_G-B0CQCQ80y-KyTejbicdg,2,1.21,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Exchange rate,Exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ForeignCurrencyExchangeRateTranslation1_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:ForeignCurrencyExchangeRateTranslation1,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,1.24,Unit_Standard_pure_G-B0CQCQ80y-KyTejbicdg,2,1.24,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Exchange rate,Exchange rate,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiability_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw_0,us-gaap:ContractWithCustomerLiability,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,184412000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,184412000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Deferred revenue,Deferred revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiability_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw_1,us-gaap:ContractWithCustomerLiability,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,184412000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,184412000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Deferred revenue,Deferred revenue,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ContractWithCustomerLiabilityRevenueRecognized_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ContractWithCustomerLiabilityRevenueRecognized,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,46784000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,46784000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Revenue recognized in the period,Revenue recognized in the period,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,283005000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,283005000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_tm5Dy5JhDEiVMO090jtaXQ,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_tm5Dy5JhDEiVMO090jtaXQ,283005000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,283005000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-03-31,None,None,None,None,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2023_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_OuBu4NJILU2NivU5dZkCrw,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2023_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_OuBu4NJILU2NivU5dZkCrw,174008000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,174008000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-03-31,None,None,None,adap:ResearchServiceRightsGrantedForInitialOffShelfCollaborationTargetsMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2023_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForPersonalizedTherapiesMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_y_Hw4U6tPkutq3mQ2OdRbg,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2023_srt_ProductOrServiceAxis_adap_ResearchServiceRightsGrantedForPersonalizedTherapiesMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_y_Hw4U6tPkutq3mQ2OdRbg,89843000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,89843000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-03-31,None,None,None,adap:ResearchServiceRightsGrantedForPersonalizedTherapiesMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2023_srt_ProductOrServiceAxis_adap_MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_cJpIpXb6F0Kfb7qW4eI8SQ,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2023_srt_ProductOrServiceAxis_adap_MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_cJpIpXb6F0Kfb7qW4eI8SQ,12929000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,12929000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-03-31,None,None,None,adap:MaterialRightToDesignateFirstAdditionalOffShelfCollaborationTargetMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2023_srt_ProductOrServiceAxis_adap_MaterialRightForFirstOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_c3q95E4Nhk2uw1n__TFmPg,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2023_srt_ProductOrServiceAxis_adap_MaterialRightForFirstOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_c3q95E4Nhk2uw1n__TFmPg,4980000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,4980000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-03-31,None,None,None,adap:MaterialRightForFirstOptionExtendResearchTermMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2023_srt_ProductOrServiceAxis_adap_MaterialRightForSecondOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_yTn2iGDgtEyLSkT7n9c4fw,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2023_srt_ProductOrServiceAxis_adap_MaterialRightForSecondOptionExtendResearchTermMember_us-gaap_TypeOfArrangementAxis_adap_StrategicCollaborationAndLicenseAgreementMember_yTn2iGDgtEyLSkT7n9c4fw,1245000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,1245000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-03-31,None,None,None,adap:MaterialRightForSecondOptionExtendResearchTermMember,adap:StrategicCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_NumberOfCoDevelopmentTarget_Duration_1_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_1WYysG9yekGE1mks68B5WQ,adap:NumberOfCoDevelopmentTarget,Duration_1_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_1WYysG9yekGE1mks68B5WQ,3,Unit_Standard_item_uIKobE5LlEe56n0bheYJnQ,INF,3.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Number of co-development targets,Number of co-development targets,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_NumberOfIndependentTargets_Duration_1_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_1WYysG9yekGE1mks68B5WQ,adap:NumberOfIndependentTargets,Duration_1_1_2023_To_3_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_1WYysG9yekGE1mks68B5WQ,2,Unit_Standard_item_uIKobE5LlEe56n0bheYJnQ,INF,2.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Number of independent targets,Number of independent targets,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails,None,None,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_TransactionPriceContractModification_As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_dCRVTKBnBEOXICr3lmu-ag,adap:TransactionPriceContractModification,As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_dCRVTKBnBEOXICr3lmu-ag,42365000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,42365000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate transaction price of the contract modification,Aggregate transaction price of the contract modification,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails,2023-03-31,None,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_dCRVTKBnBEOXICr3lmu-ag,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_dCRVTKBnBEOXICr3lmu-ag,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-03-31,None,None,None,None,us-gaap:CollaborativeArrangementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_RevenuePerformanceObligationTerminationPayment_As_Of_12_19_2022_us-gaap_TypeOfArrangementAxis_adap_GSKCollaborationAndLicenseAgreementMember_SwQHBK-Q6kiArca4ajrikw,adap:RevenuePerformanceObligationTerminationPayment,As_Of_12_19_2022_us-gaap_TypeOfArrangementAxis_adap_GSKCollaborationAndLicenseAgreementMember_SwQHBK-Q6kiArca4ajrikw,5000000,Unit_Standard_GBP_N4t8JZSo0kOxdF5S7hTHRQ,0,5000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-19,Payment by GSK due to termination of collaboration,Payment by GSK due to termination of collaboration,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGskCollaborationAndLicenseAgreementDetails,2022-12-19,None,None,None,None,adap:GSKCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_TransactionPriceContractModification_As_Of_12_19_2022_us-gaap_TypeOfArrangementAxis_adap_GSKCollaborationAndLicenseAgreementMember_SwQHBK-Q6kiArca4ajrikw,adap:TransactionPriceContractModification,As_Of_12_19_2022_us-gaap_TypeOfArrangementAxis_adap_GSKCollaborationAndLicenseAgreementMember_SwQHBK-Q6kiArca4ajrikw,6500000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,6500000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-19,Aggregate transaction price of the contract modification,Aggregate transaction price of the contract modification,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementAstellasCollaborationAgreementDetails,2022-12-19,None,None,None,None,adap:GSKCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RevenueRemainingPerformanceObligation_As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_adap_GSKCollaborationAndLicenseAgreementMember_UOHs-AlOXkKRM_AsnjdjKg,us-gaap:RevenueRemainingPerformanceObligation,As_Of_3_31_2023_us-gaap_TypeOfArrangementAxis_adap_GSKCollaborationAndLicenseAgreementMember_UOHs-AlOXkKRM_AsnjdjKg,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,0.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails,2023-03-31,None,None,None,None,adap:GSKCollaborationAndLicenseAgreementMember,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_EarningsPerShareTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:EarningsPerShareTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 4 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Profit / Loss per share</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The following tables reconcile the numerator and denominator in the basic and diluted profit/(loss) per share computation (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:25.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:25.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Numerator for basic and diluted profit/(loss) per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net profit/(loss) attributable to ordinary shareholders </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,036</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (50,265)</p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Net profit/(loss) attributable to ordinary shareholders used for basic and diluted profit/(loss) per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_vGORzIzo2UmQJ_oGxw9OmA;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,036</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_pv97TvKh1EaBKd4yEd_ZOg;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (50,265)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.91%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:24.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:24.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Denominator for basic profit/(loss) per share - Weighted average shares outstanding</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 991,330,402</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 940,029,247</p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Effect of dilutive securities:</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"">Employee stock options </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,946,213</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Denominator for diluted profit/(loss) per share</b> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,000,276,615</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 940,029,247</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The dilutive effect of 128,614,053 and 150,064,226 stock options outstanding as of March 31, 2023 and 2022 respectively have been excluded from the diluted profit/(loss) per share calculation for the three months ended March 31, 2023 and 2022 because they would have an antidilutive effect on the profit/(loss) per share for the period.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Profit/(Loss) per share,Profit/(Loss) per share,Disclosures,http://www.adaptimmune.com/role/DisclosureProfitLossPerShare,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The following tables reconcile the numerator and denominator in the basic and diluted profit/(loss) per share computation (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:25.21%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:25.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Numerator for basic and diluted profit/(loss) per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Net profit/(loss) attributable to ordinary shareholders </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,036</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (50,265)</p></td></tr><tr><td style=""vertical-align:bottom;width:72.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Net profit/(loss) attributable to ordinary shareholders used for basic and diluted profit/(loss) per share </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_vGORzIzo2UmQJ_oGxw9OmA;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,036</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""-sec-ix-hidden:Hidden_pv97TvKh1EaBKd4yEd_ZOg;""><b style=""font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"">$</b></span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (50,265)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:97.91%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:24.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""3"" style=""vertical-align:bottom;white-space:nowrap;width:24.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Denominator for basic profit/(loss) per share - Weighted average shares outstanding</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 991,330,402</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 940,029,247</p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Effect of dilutive securities:</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"">Employee stock options </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,946,213</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:73.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Denominator for diluted profit/(loss) per share</b> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,000,276,615</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 940,029,247</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Schedule of numerator and denominator in the basic and diluted loss per share computation,Schedule of numerator and denominator in the basic and diluted loss per share computation,Disclosures,http://www.adaptimmune.com/role/DisclosureProfitLossPerShareTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_3,us-gaap:NetIncomeLoss,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1036000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1036000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net profit/(loss) attributable to ordinary shareholders,Net profit/(loss) attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLoss_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_3,us-gaap:NetIncomeLoss,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-50265000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-50265000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net profit/(loss) attributable to ordinary shareholders,Net profit/(loss) attributable to ordinary shareholders,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1036000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1036000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net profit/(loss) attributable to ordinary shareholders used for basic profit/(loss) per share,Net profit/(loss) attributable to ordinary shareholders used for basic profit/(loss) per share,Disclosures,http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,-50265000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-50265000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Net profit/(loss) attributable to ordinary shareholders used for basic profit/(loss) per share,Net profit/(loss) attributable to ordinary shareholders used for basic profit/(loss) per share,Disclosures,http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_0,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,991330402,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,0,991330402.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Denominator for basic profit/(loss) per share - Weighted average shares outstanding,Denominator for basic profit/(loss) per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_1,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,991330402,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,0,991330402.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Denominator for basic profit/(loss) per share - Weighted average shares outstanding,Denominator for basic profit/(loss) per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_0,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,940029247,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,0,940029247.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Denominator for basic profit/(loss) per share - Weighted average shares outstanding,Denominator for basic profit/(loss) per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_1,us-gaap:WeightedAverageNumberOfSharesOutstandingBasic,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,940029247,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,0,940029247.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Denominator for basic profit/(loss) per share - Weighted average shares outstanding,Denominator for basic profit/(loss) per share - Weighted average shares outstanding,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,8946213,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,8946213.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Employee stock options (in shares),Employee stock options (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureProfitLossPerShareBasicAndDilutedIncomeLossPerShareDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1000276615,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,0,1000276615.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Denominator for diluted profit/(loss) per share,Denominator for diluted profit/(loss) per share,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,940029247,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,0,940029247.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Denominator for diluted profit/(loss) per share,Denominator for diluted profit/(loss) per share,IncomeStatement,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_4603i9ao3kCA0ZHbkgD1PA,us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Duration_1_1_2023_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_4603i9ao3kCA0ZHbkgD1PA,128614053,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,0,128614053.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Potentially dilutive equity instruments excluded from the diluted profit/(loss) per share (in shares),Potentially dilutive equity instruments excluded from the diluted profit/(loss) per share (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails,None,None,None,None,None,None,adap:EmployeeConsultantsAndDirectorsStockOptionsMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_Duration_1_1_2022_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_QoSNS2jNOEWFa_5Md6KGEw,us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Duration_1_1_2022_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_QoSNS2jNOEWFa_5Md6KGEw,150064226,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,0,150064226.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Potentially dilutive equity instruments excluded from the diluted profit/(loss) per share (in shares),Potentially dilutive equity instruments excluded from the diluted profit/(loss) per share (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureProfitLossPerShareAntidilutiveSharesDetails,None,None,None,None,None,None,adap:EmployeeConsultantsAndDirectorsStockOptionsMember,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ComprehensiveIncomeNoteTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ComprehensiveIncomeNoteTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 5 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Accumulated other comprehensive loss</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company reports foreign currency translation adjustments and the foreign exchange gain or losses arising on the revaluation of intercompany loans of a long-term investment nature within Other comprehensive (loss) income. Unrealized gains and losses on available-for-sale debt securities are also reported within Other comprehensive (loss) income until a gain or loss is realized, at which point they are reclassified to Other (expense) income, net in the Condensed Consolidated Statement of Operations.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">gains (losses) on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2023</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 55</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (930)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (875)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (16,908)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (16,908)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,526</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,526</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 472</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 472</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,327)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (458)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,785)</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;""> gains (losses) on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2022</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (10,785)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (357)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (11,142)</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16,792</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16,792</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (13,808)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (13,808)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding losses on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,155)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,155)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (7,801)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,512)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (9,313)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,Disclosures,http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLoss,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following tables show the changes in Accumulated other comprehensive (loss) income (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">gains (losses) on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2023</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 55</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (930)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (875)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (16,908)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (16,908)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency gains on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,526</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,526</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding gains on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 472</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 472</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,327)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (458)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,785)</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#0563c1;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Accumulated</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">foreign</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">accumulated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">currency</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;""> gains (losses) on</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">other</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">    </p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">translation </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">available-for-sale</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">comprehensive</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">adjustments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">debt securities</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">(loss) income</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Balance at January 1, 2022</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (10,785)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (357)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (11,142)</b></p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency translation adjustments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16,792</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16,792</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Foreign currency losses on intercompany loan of a long-term investment nature, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (13,808)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (13,808)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"">Unrealized holding losses on available-for-sale debt securities, net of tax of $0</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,155)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,155)</p></td></tr><tr><td style=""vertical-align:bottom;width:63.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Balance at March 31, 2022</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (7,801)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (1,512)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (9,313)</b></p></td></tr></table>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Schedule of changes in Accumulated other comprehensive (loss) income,Schedule of changes in Accumulated other comprehensive (loss) income,Disclosures,http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveLossTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_ANjzm5E7xkuUeqH9KCTm-A,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_ANjzm5E7xkuUeqH9KCTm-A,55000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,55000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_G8DbApuGAkahVGmDkeYQyw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_G8DbApuGAkahVGmDkeYQyw,-930000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-930000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J2YHUziygEarpdA5rNAp8g,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J2YHUziygEarpdA5rNAp8g,-875000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-875000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_wnmH26f54USHdVSiDCU27A,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_wnmH26f54USHdVSiDCU27A,-16908000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-16908000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mKAc0vQ8ckuSvC9SYi_zVw,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mKAc0vQ8ckuSvC9SYi_zVw,-16908000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-16908000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_0,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_1,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_wnmH26f54USHdVSiDCU27A,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_wnmH26f54USHdVSiDCU27A,15526000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,15526000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mKAc0vQ8ckuSvC9SYi_zVw,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mKAc0vQ8ckuSvC9SYi_zVw,15526000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,15526000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_0,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, tax","Unrealized holding gains (losses) on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ_1,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, tax","Unrealized holding gains (losses) on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FuT6ElTjxUSKy0G0FtTAfg,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FuT6ElTjxUSKy0G0FtTAfg,472000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,472000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mKAc0vQ8ckuSvC9SYi_zVw,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mKAc0vQ8ckuSvC9SYi_zVw,472000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,472000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_Ek_A627hlE2G8WqVipeqGg,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_Ek_A627hlE2G8WqVipeqGg,-1327000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-1327000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_2IisgoYJnUCsIUGxYEjmkQ,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_2IisgoYJnUCsIUGxYEjmkQ,-458000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-458000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ApSY2QoC7EO4lVj1RfgwHw,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ApSY2QoC7EO4lVj1RfgwHw,-1785000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-1785000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_eEBJO5VcC0uvtGg_HHSwLQ,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_eEBJO5VcC0uvtGg_HHSwLQ,-10785000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-10785000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FACvJ4Fjl0WnMQYX0aRrBA,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FACvJ4Fjl0WnMQYX0aRrBA,-357000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-357000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Hhp_QmUh00-e-76WTpFNzg,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Hhp_QmUh00-e-76WTpFNzg,-11142000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-11142000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2021-12-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2021-12-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_rH3rWYdJeUW9hSrYF-fizA,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_rH3rWYdJeUW9hSrYF-fizA,16792000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,16792000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SMQX_0CZtUe-prctzaAqMA,us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SMQX_0CZtUe-prctzaAqMA,16792000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,16792000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency translation adjustments, net of tax of $0 and $0","Foreign currency translation adjustments, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_0,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_1,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_rH3rWYdJeUW9hSrYF-fizA,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_rH3rWYdJeUW9hSrYF-fizA,-13808000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-13808000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SMQX_0CZtUe-prctzaAqMA,us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SMQX_0CZtUe-prctzaAqMA,-13808000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-13808000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0","Foreign currency gains (losses) on intercompany loan of a long-term investment nature, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_0,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, tax","Unrealized holding gains (losses) on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q_1,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, tax","Unrealized holding gains (losses) on available-for-sale debt securities, tax",ComprehensiveIncomeParenthetical,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_DDGbFnYcdEWH3lWhzg4TIQ,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_DDGbFnYcdEWH3lWhzg4TIQ,-1155000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-1155000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SMQX_0CZtUe-prctzaAqMA,us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax,Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_SMQX_0CZtUe-prctzaAqMA,-1155000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-1155000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,"Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0","Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0",ComprehensiveIncome,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss,None,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_jaYePajFfU21kKrqedWL6g,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_jaYePajFfU21kKrqedWL6g,-7801000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-7801000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:AccumulatedTranslationAdjustmentMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_akFObMcn4kaazrRCKPucBQ,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_akFObMcn4kaazrRCKPucBQ,-1512000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-1512000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1jhlfm1OyUiRHSEm4lUGpQ,us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax,As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1jhlfm1OyUiRHSEm4lUGpQ,-9313000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-9313000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Accumulated other comprehensive loss,Accumulated other comprehensive loss,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-03-31,us-gaap:AccumulatedOtherComprehensiveIncomeMember,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_FairValueDisclosuresTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:FairValueDisclosuresTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 6 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Fair value measurements</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of March 31, 2023 are as follows (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:29.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair value measurements using</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 2</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 3</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets classified as cash equivalents:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,992</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,992</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets classified as available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 40,791</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 40,791</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bonds</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,897</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,897</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 45,688</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 40,791</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 4,897</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The Company estimates the fair value of available-for-sale debt securities with the aid of a third party valuation service, which uses actual trade and indicative prices sourced from third-party providers on a daily basis to estimate the fair value. If observed market prices are not available (for example securities with short maturities and infrequent secondary market trades), the securities are priced using a valuation model maximizing observable inputs, including market interest rates.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Fair value measurements,Fair value measurements,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurements,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Assets and liabilities measured at fair value on a recurring basis based on Level 1, Level 2, and Level 3 fair value measurement criteria as of March 31, 2023 are as follows (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:29.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair value measurements using</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 1</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 2</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Level 3</b></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets classified as cash equivalents:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">U.S. Treasury securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,992</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,992</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Assets classified as available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 40,791</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 40,791</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bonds</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,897</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,897</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td></tr><tr><td style=""vertical-align:bottom;width:56.1%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 45,688</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 40,791</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 4,897</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Summary of fair value of assets and liabilities on a recurring basis based on fair value measurement criteria,Summary of fair value of assets and liabilities on a recurring basis based on fair value measurement criteria,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CashEquivalentsAtCarryingValue_As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_98WbCYDmTEG44o4sId6_-w,us-gaap:CashEquivalentsAtCarryingValue,As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_98WbCYDmTEG44o4sId6_-w,3992000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,3992000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total Cash Equivalents,Total Cash Equivalents,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails,2023-03-31,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USTreasuryBillSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CashEquivalentsAtCarryingValue_As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_PaTlEk1VuEKPSWVDxLIhUg,us-gaap:CashEquivalentsAtCarryingValue,As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryBillSecuritiesMember_PaTlEk1VuEKPSWVDxLIhUg,3992000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,3992000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total Cash Equivalents,Total Cash Equivalents,Disclosures,http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails,2023-03-31,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USTreasuryBillSecuritiesMember,us-gaap:FairValueInputsLevel2Member,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_hnACfMV-aUCv2mNkSR0gPA,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_hnACfMV-aUCv2mNkSR0gPA,40791000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,40791000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_XYcns1bM0UmAokES2FN2Eg,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_XYcns1bM0UmAokES2FN2Eg,40791000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,40791000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:CorporateDebtSecuritiesMember,us-gaap:FairValueInputsLevel1Member,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_k_jgUEVPnk-nKdpujV5WwA,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_k_jgUEVPnk-nKdpujV5WwA,4897000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4897000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_33j-3SEQGkCEbPvo_H-bzQ,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_33j-3SEQGkCEbPvo_H-bzQ,4897000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4897000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,us-gaap:FairValueInputsLevel2Member,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1AojlgwKX0ODag9O8vk92A,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1AojlgwKX0ODag9O8vk92A,45688000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,45688000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9CDrNBKjN0KyGinIqKQP1A,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9CDrNBKjN0KyGinIqKQP1A,40791000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,40791000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,us-gaap:FairValueInputsLevel1Member,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_V09VYNa5CUizcfz96nMyKA,us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent,As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_V09VYNa5CUizcfz96nMyKA,4897000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4897000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,us-gaap:FairValueMeasurementsRecurringMember,None,us-gaap:FairValueInputsLevel2Member,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 7 — Marketable securities – available-for-sale debt securities</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of March 31, 2023, the Company has the following investments in marketable securities (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.089717865%;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Aggregate</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Remaining</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Amortized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">estimated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">contractual maturity</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">cost</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">gains</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">fair value</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;"">  </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 25,527</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (131)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 25,396</p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bonds</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">3 months to 1 year</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,000</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (103)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,897</p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">3 months to 1 year</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,619</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (224)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,395</p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 46,146</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (458)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 45,688</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of March 31, 2023 and December 31, 2022 are as follows: </p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, 2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:26.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, 2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Marketable securities in a continuous loss position for 12 months or longer:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 40,791</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (355)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 74,481</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (679)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bond</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,897</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (103)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,854</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (154)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Marketable securities in a continuous loss position for less than 12 months:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,283</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (97)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 45,688</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 10</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (458)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 90,618</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 19</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (930)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of March 31, 2023, no allowance for expected credit losses has been recognized in relation to securities in an unrealized loss position. This is because the impairments are not severe, do not represent a significant proportion of the total fair market value of the investments and all securities have an investment-grade credit rating. Furthermore, the Company does not intend to sell the debt securities in an unrealized loss position, believes that it has the ability to hold the debt securities to maturity, and it is currently unlikely that the Company will be required to sell these securities before the recovery of the amortized cost.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Marketable securities - available-for-sale debt securities,Marketable securities - available-for-sale debt securities,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecurities,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">As of March 31, 2023, the Company has the following investments in marketable securities (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.089717865%;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Gross</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Aggregate</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Remaining</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Amortized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">unrealized</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">estimated</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">contractual maturity</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">cost</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">gains</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">fair value</b></p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Available-for-sale debt securities:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;"">  </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">Less than 3 months</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 25,527</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (131)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 25,396</p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bonds</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">3 months to 1 year</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,000</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (103)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,897</p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"">3 months to 1 year</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,619</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (224)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 15,395</p></td></tr><tr><td style=""vertical-align:bottom;width:40.53%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">  </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 46,146</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (458)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 45,688</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Schedule of marketable securities,Schedule of marketable securities,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_9n3EzO5ee0G9-6WSFm_L5g,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_9n3EzO5ee0G9-6WSFm_L5g,P3M,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,srt:MaximumMember,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_qAxe3G5ZB0qq8mWDDpD7nw,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_qAxe3G5ZB0qq8mWDDpD7nw,25527000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,25527000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_qAxe3G5ZB0qq8mWDDpD7nw,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_qAxe3G5ZB0qq8mWDDpD7nw,131000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,131000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_qAxe3G5ZB0qq8mWDDpD7nw,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember_qAxe3G5ZB0qq8mWDDpD7nw,25396000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,25396000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_p_thd3rMOk29O_0OMVDWVA,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_p_thd3rMOk29O_0OMVDWVA,P3M,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,None,adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember,None,srt:MinimumMember,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_YrPYDtTU00ehbkdKYz-PlQ,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_YrPYDtTU00ehbkdKYz-PlQ,P1Y,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,None,adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember,None,srt:MaximumMember,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_GFehSPywhkqZQcvJvqanVw,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_GFehSPywhkqZQcvJvqanVw,5000000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,5000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_GFehSPywhkqZQcvJvqanVw,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_GFehSPywhkqZQcvJvqanVw,103000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,103000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_GFehSPywhkqZQcvJvqanVw,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember_GFehSPywhkqZQcvJvqanVw,4897000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4897000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,adap:AgencyBondMaturityPeriodThreeMonthsToOneYearMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_HZ7Xj1KeiEW0jLKIt5i_qQ,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_HZ7Xj1KeiEW0jLKIt5i_qQ,P3M,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,srt:MinimumMember,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_AvailableForSaleSecuritiesDebtMaturityPeriod_Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_o-TfARq5_UGFBvEeglrLMw,adap:AvailableForSaleSecuritiesDebtMaturityPeriod,Duration_1_1_2023_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_o-TfARq5_UGFBvEeglrLMw,P1Y,None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Available For Sale Securities Debt Maturity Period,Available For Sale Securities Debt Maturity Period,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,None,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,srt:MaximumMember,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_Pv3KUc5aNUG4v1FI70dQaw,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_Pv3KUc5aNUG4v1FI70dQaw,15619000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,15619000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_Pv3KUc5aNUG4v1FI70dQaw,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_Pv3KUc5aNUG4v1FI70dQaw,224000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,224000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_Pv3KUc5aNUG4v1FI70dQaw,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_us-gaap_FinancialInstrumentAxis_adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember_Pv3KUc5aNUG4v1FI70dQaw,15395000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,15395000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,adap:CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_83eflh1IK0qv3PMTCl1s5Q,us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis,As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_83eflh1IK0qv3PMTCl1s5Q,46146000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,46146000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Amortized cost,Amortized cost,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_83eflh1IK0qv3PMTCl1s5Q,us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax,As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_83eflh1IK0qv3PMTCl1s5Q,458000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,458000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Gross unrealized losses,Gross unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AvailableForSaleSecuritiesDebtSecurities_As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_83eflh1IK0qv3PMTCl1s5Q,us-gaap:AvailableForSaleSecuritiesDebtSecurities,As_Of_3_31_2023_us-gaap_FairValueByAssetClassAxis_us-gaap_DebtSecuritiesMember_83eflh1IK0qv3PMTCl1s5Q,45688000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,45688000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Aggregate estimated fair value,Aggregate estimated fair value,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,us-gaap:DebtSecuritiesMember,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The aggregate fair value (in thousands) and number of securities held by the Company (including those classified as cash equivalents) in an unrealized loss position as of March 31, 2023 and December 31, 2022 are as follows: </p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, 2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""8"" style=""vertical-align:bottom;white-space:nowrap;width:26.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, 2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Fair market value of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Number of investments in an unrealized loss position</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Unrealized losses</b></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Marketable securities in a continuous loss position for 12 months or longer:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 40,791</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (355)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 74,481</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (679)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Agency bond</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,897</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (103)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,854</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (154)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Marketable securities in a continuous loss position for less than 12 months:</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Corporate debt securities </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> —</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 11,283</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (97)</p></td></tr><tr><td style=""vertical-align:bottom;width:41.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 45,688</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 10</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (458)</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 90,618</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 19</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><b style=""font-weight:bold;""> (930)</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Schedule of aggregate fair value and number of securities held by the Company in an unrealized loss position,Schedule of aggregate fair value and number of securities held by the Company in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ydd9BaO9xUOMCCnFvVl-yw,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger,As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ydd9BaO9xUOMCCnFvVl-yw,40791000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,40791000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Fair market value of investments in an unrealized loss position, 12 months or longer","Fair market value of investments in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2023-03-31,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ydd9BaO9xUOMCCnFvVl-yw,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions,As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ydd9BaO9xUOMCCnFvVl-yw,-9,Unit_Standard_security_e20N1rxXFEqVi1ysJtNUVg,INF,-9.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Number of available-for-sale securities in an unrealized loss position, 12 months or longer","Number of available-for-sale securities in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2023-03-31,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ydd9BaO9xUOMCCnFvVl-yw,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss,As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Ydd9BaO9xUOMCCnFvVl-yw,355000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,355000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Unrealized losses, 12 months or longer","Unrealized losses, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2023-03-31,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger,As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,74481000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,74481000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Fair market value of investments in an unrealized loss position, 12 months or longer","Fair market value of investments in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions,As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,-16,Unit_Standard_security_e20N1rxXFEqVi1ysJtNUVg,INF,-16.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Number of available-for-sale securities in an unrealized loss position, 12 months or longer","Number of available-for-sale securities in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss,As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,679000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,679000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Unrealized losses, 12 months or longer","Unrealized losses, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_W1Venn7YlECy97myxcEaAA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger,As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_W1Venn7YlECy97myxcEaAA,4897000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4897000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Fair market value of investments in an unrealized loss position, 12 months or longer","Fair market value of investments in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2023-03-31,None,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_W1Venn7YlECy97myxcEaAA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions,As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_W1Venn7YlECy97myxcEaAA,-1,Unit_Standard_security_e20N1rxXFEqVi1ysJtNUVg,INF,-1.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Number of available-for-sale securities in an unrealized loss position, 12 months or longer","Number of available-for-sale securities in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2023-03-31,None,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_W1Venn7YlECy97myxcEaAA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss,As_Of_3_31_2023_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_W1Venn7YlECy97myxcEaAA,103000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,103000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Unrealized losses, 12 months or longer","Unrealized losses, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2023-03-31,None,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_NW2ho_4P2Uq4cBC3wgHvtw,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger,As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_NW2ho_4P2Uq4cBC3wgHvtw,4854000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4854000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Fair market value of investments in an unrealized loss position, 12 months or longer","Fair market value of investments in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_NW2ho_4P2Uq4cBC3wgHvtw,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions,As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_NW2ho_4P2Uq4cBC3wgHvtw,-1,Unit_Standard_security_e20N1rxXFEqVi1ysJtNUVg,INF,-1.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Number of available-for-sale securities in an unrealized loss position, 12 months or longer","Number of available-for-sale securities in an unrealized loss position, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_NW2ho_4P2Uq4cBC3wgHvtw,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss,As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_NW2ho_4P2Uq4cBC3wgHvtw,154000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,154000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Unrealized losses, 12 months or longer","Unrealized losses, 12 months or longer",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months,As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,11283000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,11283000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Fair market value of investments in an unrealized loss position, less than 12 months","Fair market value of investments in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions,As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,-2,Unit_Standard_security_e20N1rxXFEqVi1ysJtNUVg,INF,-2.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Number of available-for-sale securities in an unrealized loss position, less than 12 months","Number of available-for-sale securities in an unrealized loss position, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss,As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_2F2LXr4wEEqhTETvCufrGA,97000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,97000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Unrealized losses, less than 12 months","Unrealized losses, less than 12 months",Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,us-gaap:CorporateDebtSecuritiesMember,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,45688000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,45688000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Fair market value of investments in an unrealized loss position,Fair market value of investments in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,10,Unit_Standard_security_e20N1rxXFEqVi1ysJtNUVg,0,10.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Number of investments in an unrealized loss position,Number of investments in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,458000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,458000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Unrealized losses,Unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,90618000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,90618000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Fair market value of investments in an unrealized loss position,Fair market value of investments in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,19,Unit_Standard_security_e20N1rxXFEqVi1ysJtNUVg,INF,19.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Number of investments in an unrealized loss position,Number of investments in an unrealized loss position,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,930000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,930000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Unrealized losses,Unrealized losses,Disclosures,http://www.adaptimmune.com/role/DisclosureMarketableSecuritiesAvailableForSaleDebtSecuritiesUnrealizedLossPositionDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherCurrentAssetsTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:OtherCurrentAssetsTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 8 — Other current assets</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Other current assets consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development credits receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 36,363</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 30,162</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Prepayments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,787</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9,472</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Clinical materials</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,310</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,279</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">VAT receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 355</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 490</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other current assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,664</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,927</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 46,479</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 43,330</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssets,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Other current assets consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development credits receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 36,363</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 30,162</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Prepayments</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6,787</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 9,472</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Clinical materials</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,310</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,279</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">VAT receivable</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 355</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 490</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other current assets</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,664</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,927</p></td></tr><tr><td style=""vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 46,479</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 43,330</b></p></td></tr></table>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Summary of other current assets,Summary of other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_TaxCreditReceivableCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,adap:TaxCreditReceivableCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,36363000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,36363000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Research and development credits receivable,Research and development credits receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_TaxCreditReceivableCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,adap:TaxCreditReceivableCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,30162000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,30162000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Research and development credits receivable,Research and development credits receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:PrepaidExpenseCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,6787000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,6787000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Prepayments,Prepayments,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PrepaidExpenseCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:PrepaidExpenseCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,9472000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,9472000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Prepayments,Prepayments,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_ClinicalMaterialsCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,adap:ClinicalMaterialsCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,1310000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1310000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Clinical materials,Clinical materials,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_ClinicalMaterialsCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,adap:ClinicalMaterialsCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,1279000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1279000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Clinical materials,Clinical materials,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ValueAddedTaxReceivableCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:ValueAddedTaxReceivableCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,355000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,355000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,VAT receivable,VAT receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ValueAddedTaxReceivableCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:ValueAddedTaxReceivableCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,490000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,490000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,VAT receivable,VAT receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherAssetsCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:OtherAssetsCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,1664000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1664000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherAssetsCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:OtherAssetsCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,1927000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1927000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Other current assets,Other current assets,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,adap:PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,46479000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,46479000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,adap:PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,43330000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,43330000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Total,Total,Disclosures,http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeasesTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:LesseeOperatingLeasesTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 9 — Operating leases</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The Company has operating leases in relation to property for office, manufacturing and research facilities<span style=""font-size:12pt;"">. </span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On March 21, 2023, the Company entered into an agreement to extend a manufacturing facility agreement that contains an embedded lease that was accounted for under ASC 842 <i style=""font-style:italic;"">Leases.</i> The effect of the modification was an extension of the lease term and a corresponding increase in contractual lease payments for the extended term. Upon modification, the lease liability has been remeasured using the current estimate of the Company’s incremental borrowing rate. The effect of the modification was to increase the lease liability and the corresponding right-of-use asset by $349,000.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the weighted-average remaining lease term and the weighted-average discount rate as at March 31, 2023 and 2022:</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average remaining lease term - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">6.7 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">7.6 years</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average discount rate - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;""><span style=""font-size:0pt;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The maturities of operating lease liabilities as of March 31, 2023 are as follows (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#111111;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Operating leases</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2023</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,267</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,003</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,051</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2026</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,104</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2027</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,521</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">after 2027</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,504</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total lease payments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 28,450</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Less: Imputed interest</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5,617)</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Present value of lease liability</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 22,833</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The maximum lease term without activation of termination options is to 2041. </p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Operating leases,Operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeases,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_AmountOfIncreaseDecreaseInObligationAndRightOfUseAssetForOperatingLeaseFollowingLeaseModification_Duration_3_21_2023_To_3_21_2023__LNyQSzNiESv2N9-LYELdA,adap:AmountOfIncreaseDecreaseInObligationAndRightOfUseAssetForOperatingLeaseFollowingLeaseModification,Duration_3_21_2023_To_3_21_2023__LNyQSzNiESv2N9-LYELdA,349000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,349000.0,duration,2023-03-21,2023-03-21,0001621227,http://www.sec.gov/CIK,duration_2023-03-21_2023-03-21,Amount of increase (decrease) in obligation and right-of-use asset for operating lease following lease modification,Amount of increase (decrease) in obligation and right-of-use asset for operating lease following lease modification,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,adap:WeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows the weighted-average remaining lease term and the weighted-average discount rate as at March 31, 2023 and 2022:</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""5"" style=""vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average remaining lease term - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">6.7 years</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">7.6 years</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:41.65%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted-average discount rate - operating leases</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:28.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><span style=""font-family:'Times';"">6.8%</span></p></td></tr></table>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Schedule of weighted-average remaining lease term and the weighted-average discount rate,Schedule of weighted-average remaining lease term and the weighted-average discount rate,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,P6Y8M12D,None,None,,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Weighted-average remaining lease term - operating leases,Weighted-average remaining lease term - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_As_Of_3_31_2022_wzEb70mnG063uVdzeBzGKw,us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1,As_Of_3_31_2022_wzEb70mnG063uVdzeBzGKw,P7Y7M6D,None,None,,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Weighted-average remaining lease term - operating leases,Weighted-average remaining lease term - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2022-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,0.068,Unit_Standard_pure_G-B0CQCQ80y-KyTejbicdg,3,0.068,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Weighted-average discount rate - operating leases,Weighted-average discount rate - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_As_Of_3_31_2022_wzEb70mnG063uVdzeBzGKw,us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent,As_Of_3_31_2022_wzEb70mnG063uVdzeBzGKw,0.068,Unit_Standard_pure_G-B0CQCQ80y-KyTejbicdg,3,0.068,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-03-31,Weighted-average discount rate - operating leases,Weighted-average discount rate - operating leases,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetails,2022-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The maturities of operating lease liabilities as of March 31, 2023 are as follows (in thousands):</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""color:#111111;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">     </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Operating leases</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:20.71%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2023</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,267</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2024</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,003</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2025</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,051</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2026</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,104</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">2027</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 5,521</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">after 2027</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;""> </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,504</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total lease payments</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 28,450</b></p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Less: Imputed interest</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (5,617)</p></td></tr><tr><td style=""vertical-align:bottom;width:75.52%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Present value of lease liability</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 22,833</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Schedule of maturities of operating lease liabilities,Schedule of maturities of operating lease liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,3267000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,3267000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,2023,2023,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,4003000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4003000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,2024,2024,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,4051000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4051000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,2025,2025,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,4104000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4104000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,2026,2026,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,5521000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,5521000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,2027,2027,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,7504000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,7504000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,after 2027,after 2027,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,28450000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,28450000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total lease payments,Total lease payments,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,5617000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,5617000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Less: Imputed interest,Less: Imputed interest,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OperatingLeaseLiability_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:OperatingLeaseLiability,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,22833000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,22833000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Present value of lease liability,Present value of lease liability,Disclosures,http://www.adaptimmune.com/role/DisclosureOperatingLeasesMaturitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 10 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Accrued expenses and other current liabilities</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued clinical and development expenditure</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 17,811</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16,749</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued employee expenses</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,780</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,232</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other accrued expenditure</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,850</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,079</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,769</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,155</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 33,210</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 31,215</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Accrued expenses and other current liabilities consisted of the following (in thousands):</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">December 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued clinical and development expenditure</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 17,811</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 16,749</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Accrued employee expenses</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,780</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8,232</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other accrued expenditure</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 7,850</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 4,079</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Other</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,769</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,155</p></td></tr><tr><td style=""vertical-align:bottom;width:65.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 33,210</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 31,215</b></p></td></tr></table>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Schedule of accrued expenses and other current liabilities,Schedule of accrued expenses and other current liabilities,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_AccruedLiabilitiesForPurchasesCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,adap:AccruedLiabilitiesForPurchasesCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,17811000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,17811000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accrued clinical and development expenditure,Accrued clinical and development expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_AccruedLiabilitiesForPurchasesCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,adap:AccruedLiabilitiesForPurchasesCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,16749000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,16749000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accrued clinical and development expenditure,Accrued clinical and development expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_EmployeeRelatedLiabilitiesCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:EmployeeRelatedLiabilitiesCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,4780000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4780000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accrued employee expenses,Accrued employee expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_EmployeeRelatedLiabilitiesCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:EmployeeRelatedLiabilitiesCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,8232000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,8232000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accrued employee expenses,Accrued employee expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherAccruedLiabilitiesCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:OtherAccruedLiabilitiesCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,7850000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,7850000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Other accrued expenditure,Other accrued expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherAccruedLiabilitiesCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:OtherAccruedLiabilitiesCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,4079000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,4079000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Other accrued expenditure,Other accrued expenditure,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:OtherLiabilitiesCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,2769000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,2769000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Other,Other,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_OtherLiabilitiesCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:OtherLiabilitiesCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,2155000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,2155000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Other,Other,Disclosures,http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_0,us-gaap:AccruedLiabilitiesCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,33210000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,33210000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_1,us-gaap:AccruedLiabilitiesCurrent,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,33210000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,33210000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw_0,us-gaap:AccruedLiabilitiesCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,31215000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,31215000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AccruedLiabilitiesCurrent_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw_1,us-gaap:AccruedLiabilitiesCurrent,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,31215000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,31215000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Accrued expenses and other current liabilities,Accrued expenses and other current liabilities,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:CommitmentsAndContingenciesDisclosureTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 11 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Contingencies and commitments</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">Universal Cells Research, Collaboration and License Agreement and </i><i style=""font-style:italic;"">Co-development and Co-commercialization agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On November 25, 2015, the Company entered into a Research, Collaboration and License Agreement relating to gene editing and Human Leukocyte Antigen (“HLA”) engineering technology with Universal Cells, Inc. (“Universal Cells”). The Company paid an upfront license and start-up fee of $2,500,000 to Universal Cells in November 2015, a milestone payment of $3,000,000 in February 2016 and further milestone payments of $200,000 and $900,000 were made in the years ended December 31, 2018 and 2017, respectively.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;background:#ffff00;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The agreement was amended and re-stated as of January 13, 2020, primarily to reflect changes to the development plan agreed between the parties. The agreement was further amended as of July 22, 2022, primarily to make certain changes to development milestones and to agree on the status thereof, as agreed between the parties. Following the amendment, milestone payments of $500,000, $600,000 and $400,000 were made in the year ended December 31, 2022. A further milestone of $1,800,000 has been accrued but not paid as of March 31, 2023. The upfront license and start-up fee and milestone payments were expensed to Research and development when incurred.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">This Agreement was terminated by notice on January 27, 2023, effective 30 days following receipt of notice of termination. As a result of termination, all licenses between the parties to the Agreement will cease and each party is required to return all confidential information of the other party.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;"">Astellas Collaboration Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-style:italic;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">Under the Astellas Collaboration Agreement, described further in Note 3, if Adaptimmune had unilaterally developed a product with technology contributed by Astellas, Astellas could have been eligible to receive milestones and royalties relating to future commercialization and sales. As a result of the termination of the collaboration, Astellas no longer has the right to receive these milestones or royalties in future.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><i style=""font-style:italic;"">MD Anderson Strategic Alliance</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On September 26, 2016, the Company announced that it had entered into a multi-year strategic alliance with The University of Texas MD Anderson Cancer Center (“MD Anderson”) designed to expedite the development of T-cell therapies for multiple types of cancer. The Company and MD Anderson are collaborating on a number of studies including clinical and preclinical development of the Company’s SPEAR T-cell therapies and will collaborate on future clinical stage first and second generation SPEAR T-cell therapies across a number of cancers.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">Under the terms of the agreement, the Company committed at least $19,644,000 to fund studies. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance and the performance of set milestones by MD Anderson. The Company made an upfront payment of $3,412,000 to MD Anderson in the year ended December 31, 2017 and milestone payments of $2,326,000, $3,549,000, $454,000 and $2,326,000 in the years ended December 31, 2018, 2020, 2021, and 2022, respectively. The Company is obligated to make further payments to MD Anderson as certain milestones are achieved. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, amongst other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Contingencies and commitments,Contingencies and commitments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitments,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_LicenseAgreementUpfrontLicenseAndStartUpFees_Duration_11_1_2015_To_11_30_2015_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_4k9Qj6CU00--J-m0Cb7BUA,adap:LicenseAgreementUpfrontLicenseAndStartUpFees,Duration_11_1_2015_To_11_30_2015_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_4k9Qj6CU00--J-m0Cb7BUA,2500000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,2500000.0,duration,2015-11-01,2015-11-30,0001621227,http://www.sec.gov/CIK,duration_2015-11-01_2015-11-30,Upfront license and start-up fees,Upfront license and start-up fees,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,adap:CollaborationAndLicenseAgreementMember,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePayments_Duration_2_1_2016_To_2_29_2016_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_H-Zf9nn6XUeX33c5rUZCqA,adap:LicenseAgreementMilestonePayments,Duration_2_1_2016_To_2_29_2016_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_H-Zf9nn6XUeX33c5rUZCqA,3000000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,3000000.0,duration,2016-02-01,2016-02-29,0001621227,http://www.sec.gov/CIK,duration_2016-02-01_2016-02-29,Milestone payments,Milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,adap:CollaborationAndLicenseAgreementMember,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePayments_Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_Ks0roWW36USK2AABUln_wQ,adap:LicenseAgreementMilestonePayments,Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_Ks0roWW36USK2AABUln_wQ,200000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,200000.0,duration,2018-01-01,2018-12-31,0001621227,http://www.sec.gov/CIK,duration_2018-01-01_2018-12-31,Milestone payments,Milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,adap:CollaborationAndLicenseAgreementMember,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePayments_Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_UJZ300YfRUSX3rKANzNOGg,adap:LicenseAgreementMilestonePayments,Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_UJZ300YfRUSX3rKANzNOGg,900000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,900000.0,duration,2017-01-01,2017-12-31,0001621227,http://www.sec.gov/CIK,duration_2017-01-01_2017-12-31,Milestone payments,Milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,adap:CollaborationAndLicenseAgreementMember,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePaymentOne_As_Of_12_31_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_UZZg_fwfWUyPlpbCeeERuA,adap:LicenseAgreementMilestonePaymentOne,As_Of_12_31_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_UZZg_fwfWUyPlpbCeeERuA,500000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,500000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,First milestone payment,First milestone payment,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,adap:CollaborationAndLicenseAgreementMember,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePaymentTwo_As_Of_12_31_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_UZZg_fwfWUyPlpbCeeERuA,adap:LicenseAgreementMilestonePaymentTwo,As_Of_12_31_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_UZZg_fwfWUyPlpbCeeERuA,600000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,600000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Second milestone payment,Second milestone payment,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,adap:CollaborationAndLicenseAgreementMember,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePaymentThree_As_Of_12_31_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_UZZg_fwfWUyPlpbCeeERuA,adap:LicenseAgreementMilestonePaymentThree,As_Of_12_31_2022_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_UZZg_fwfWUyPlpbCeeERuA,400000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,400000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Third milestone payment,Third milestone payment,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,adap:CollaborationAndLicenseAgreementMember,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_LicenseAgreementMilestonePaymentAccruedButNotYetPaid_As_Of_3_31_2023_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_zKSRBBeMQ0iwlVbtPc9Z0A,adap:LicenseAgreementMilestonePaymentAccruedButNotYetPaid,As_Of_3_31_2023_srt_CounterpartyNameAxis_adap_UniversalCellsIncMember_us-gaap_OtherCommitmentsAxis_adap_CollaborationAndLicenseAgreementMember_zKSRBBeMQ0iwlVbtPc9Z0A,1800000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1800000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Milestone payment accrued but not yet paid,Milestone payment accrued but not yet paid,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsUniversalCellsResearchCollaborationAndLicenseAgreementAndCoDevelopmentAndCoCommercializationAgreementDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,adap:UniversalCellsIncMember,adap:CollaborationAndLicenseAgreementMember,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_MilestoneAmountPayable_As_Of_9_26_2016_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_srt_RangeAxis_srt_MinimumMember_2hTn2gMBckWXBicHnZQUwg,adap:MilestoneAmountPayable,As_Of_9_26_2016_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_srt_RangeAxis_srt_MinimumMember_2hTn2gMBckWXBicHnZQUwg,19644000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,19644000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2016-09-26,Potential milestone payments,Potential milestone payments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,2016-09-26,None,None,None,None,None,None,None,None,None,srt:MinimumMember,None,adap:MDAndersonStrategicAllianceMember,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_UpfrontPayment_Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_V84n-gl7EU-sU8h4mz8O9g,adap:UpfrontPayment,Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_V84n-gl7EU-sU8h4mz8O9g,3412000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,3412000.0,duration,2017-01-01,2017-12-31,0001621227,http://www.sec.gov/CIK,duration_2017-01-01_2017-12-31,Upfront payment,Upfront payment,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,None,None,None,None,None,None,None,None,None,None,None,None,adap:MDAndersonStrategicAllianceMember,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_qt71wnt_yUa4dg3DIuYXAQ,adap:MilestonePayments,Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_qt71wnt_yUa4dg3DIuYXAQ,2326000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,2326000.0,duration,2018-01-01,2018-12-31,0001621227,http://www.sec.gov/CIK,duration_2018-01-01_2018-12-31,Milestone Payments,Milestone Payments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,None,None,None,None,None,None,None,None,None,None,None,None,adap:MDAndersonStrategicAllianceMember,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_e1a2fOLQwEeH9rg3a-MNQg,adap:MilestonePayments,Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_e1a2fOLQwEeH9rg3a-MNQg,3549000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,3549000.0,duration,2020-01-01,2020-12-31,0001621227,http://www.sec.gov/CIK,duration_2020-01-01_2020-12-31,Milestone Payments,Milestone Payments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,None,None,None,None,None,None,None,None,None,None,None,None,adap:MDAndersonStrategicAllianceMember,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_VizNyvIL_Ui5H5Oqz6818w,adap:MilestonePayments,Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_VizNyvIL_Ui5H5Oqz6818w,454000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,454000.0,duration,2021-01-01,2021-12-31,0001621227,http://www.sec.gov/CIK,duration_2021-01-01_2021-12-31,Milestone Payments,Milestone Payments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,None,None,None,None,None,None,None,None,None,None,None,None,adap:MDAndersonStrategicAllianceMember,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_MilestonePayments_Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_c6DECjixGkWqSD85g6mgpA,adap:MilestonePayments,Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_adap_MDAndersonStrategicAllianceMember_c6DECjixGkWqSD85g6mgpA,2326000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,2326000.0,duration,2022-01-01,2022-12-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-12-31,Milestone Payments,Milestone Payments,Disclosures,http://www.adaptimmune.com/role/DisclosureContingenciesAndCommitmentsMdAndersonStrategicAllianceDetails,None,None,None,None,None,None,None,None,None,None,None,None,adap:MDAndersonStrategicAllianceMember,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 12 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Share-based compensation</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The share-based compensation expense decrease is driven largely by additional forefeitures of $1,796,500 in the quarter <span style=""white-space:pre-wrap;"">as a result of the recent restructuring.  The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:66.46%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 116</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,523</p></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">General and administrative</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,560</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,063</p></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,676</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 5,586</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of options over ordinary shares granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">21,755,328</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">22,876,464</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of ordinary shares options</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.25</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.43</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of additional options with a nominal exercise price granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">19,866,912</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">17,688,432</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of options with a nominal exercise price </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.32</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.59</p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Share-based compensation,Share-based compensation,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensation,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The share-based compensation expense decrease is driven largely by additional forefeitures of $1,796,500 in the quarter <span style=""white-space:pre-wrap;"">as a result of the recent restructuring.  The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:66.46%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Research and development</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 116</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,523</p></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">General and administrative</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,560</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""> </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 3,063</p></td></tr><tr><td style=""vertical-align:bottom;width:66.46%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,676</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 5,586</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Summary of share-based compensation expense included in the consolidated statements of operations,Summary of share-based compensation expense included in the consolidated statements of operations,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1796500,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,1796500.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Shares forfeited,Shares forfeited,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_EU7A9GqrBEyNAKDOlcsH3g,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_EU7A9GqrBEyNAKDOlcsH3g,116000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,116000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchAndDevelopmentExpenseMember,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_28B2OF4G90S5yBo22lbdhw,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_28B2OF4G90S5yBo22lbdhw,2523000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,2523000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ResearchAndDevelopmentExpenseMember,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_aTeMSwt7Y0qlw2S4GHvp9Q,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_aTeMSwt7Y0qlw2S4GHvp9Q,1560000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1560000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:GeneralAndAdministrativeExpenseMember,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JdhCGFvSDUuRNO93tPy5eA,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_JdhCGFvSDUuRNO93tPy5eA,3063000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,3063000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:GeneralAndAdministrativeExpenseMember,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1676000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1676000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_AllocatedShareBasedCompensationExpense_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:AllocatedShareBasedCompensationExpense,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,5586000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,5586000.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Total share-based compensation expense,Total share-based compensation expense,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:</p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.45%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Three months ended </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""4"" style=""vertical-align:bottom;white-space:nowrap;width:28.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">March 31, </b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:14.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">2022</b></p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of options over ordinary shares granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">21,755,328</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">22,876,464</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of ordinary shares options</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.25</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.43</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Number of additional options with a nominal exercise price granted</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">19,866,912</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">17,688,432</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:66.46%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Weighted average fair value of options with a nominal exercise price </p></td><td style=""vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.32</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:13.03%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"">0.59</p></td></tr></table>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Summary of all stock option activity,Summary of all stock option activity,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,21755328,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,21755328.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Number of options over ordinary shares granted (in shares),Number of options over ordinary shares granted (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,22876464,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,22876464.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Number of options over ordinary shares granted (in shares),Number of options over ordinary shares granted (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0.25,Unit_Divide_USD_shares_37vC64oj8EqSLVdm8zK4dw,2,0.25,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Weighted average fair value of ordinary shares options (in dollars per share),Weighted average fair value of ordinary shares options (in dollars per share),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,0.43,Unit_Divide_USD_shares_37vC64oj8EqSLVdm8zK4dw,2,0.43,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Weighted average fair value of ordinary shares options (in dollars per share),Weighted average fair value of ordinary shares options (in dollars per share),Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,19866912,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,19866912.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Number of additional options with a nominal exercise price granted,Number of additional options with a nominal exercise price granted,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,17688432,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,17688432.0,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Number of additional options with a nominal exercise price granted,Number of additional options with a nominal exercise price granted,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0.32,Unit_Divide_USD_shares_37vC64oj8EqSLVdm8zK4dw,2,0.32,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Weighted average fair value of options with a nominal exercise price,Weighted average fair value of options with a nominal exercise price,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice_Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,adap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice,Duration_1_1_2022_To_3_31_2022_oomSVwA-akC0dFDCn2rm7Q,0.59,Unit_Divide_USD_shares_37vC64oj8EqSLVdm8zK4dw,2,0.59,duration,2022-01-01,2022-03-31,0001621227,http://www.sec.gov/CIK,duration_2022-01-01_2022-03-31,Weighted average fair value of options with a nominal exercise price,Weighted average fair value of options with a nominal exercise price,Disclosures,http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockholdersEquityNoteDisclosureTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:StockholdersEquityNoteDisclosureTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;""><b style=""font-weight:bold;"">Note 13 </b><b style=""font-weight:bold;"">—</b><b style=""font-weight:bold;""> Stockholders’ equity</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"">On August 10, 2020 the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”) (the “Sales Agreement”) under which we may from time to time issue and sell American Depositary Shares (“ADSs”) representing our ordinary shares through Cowen in at-the-market (“ATM”) offerings for an aggregate offering price of up to $200 million. As of March 31, 2023, $197,360,000 remained available for sale under the Sales Agreement. </p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On April 8, 2022 the Company entered into a new sales agreement with Cowen (the “2022 Sales Agreement”) under which we may from time to time issue and sell ADSs representing our ordinary shares through Cowen in ATM offerings for an aggregate offering price of up to $200 million. In the three months ended March 31, 2023, the Company sold 92,416 ADSs under the agreement representing 554,496 ordinary shares resulting in net proceeds to the Company of $173,430 after deducting commissions payable under the 2022 Sales Agreement and estimated issuance costs. As of March 31, 2023, approximately $186,513,100<span style=""white-space:pre-wrap;""> remained available for sale under the 2022 Sales Agreement.  </span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Stockholders' equity,Stockholders' equity,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_StockIssuedDuringPeriodValueSalesAgreement_Duration_8_10_2020_To_8_10_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreementMember_xHvuGyFCgUakVdMDcWPAXQ,adap:StockIssuedDuringPeriodValueSalesAgreement,Duration_8_10_2020_To_8_10_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreementMember_xHvuGyFCgUakVdMDcWPAXQ,200000000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-6,200000000.0,duration,2020-08-10,2020-08-10,0001621227,http://www.sec.gov/CIK,duration_2020-08-10_2020-08-10,Aggregate offering price of ADS shares under At The Market sales agreement,Aggregate offering price of ADS shares under At The Market sales agreement,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,None,None,None,None,None,None,None,None,None,None,srt:MaximumMember,None,None,None,None,adap:SalesAgreementMember,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_StockIssuedSalesAgreementRemainingAmountAvailableForSale_Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreementMember_4GnITsgL8UOZ06N57pgBUw,adap:StockIssuedSalesAgreementRemainingAmountAvailableForSale,Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreementMember_4GnITsgL8UOZ06N57pgBUw,197360000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,197360000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Remaining amount under the Sales Agreement,Remaining amount under the Sales Agreement,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreementMember,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_StockIssuedDuringPeriodValueSalesAgreement_Duration_4_8_2022_To_4_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_VtSc6lRNJUK3POasFJuMGA,adap:StockIssuedDuringPeriodValueSalesAgreement,Duration_4_8_2022_To_4_8_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_VtSc6lRNJUK3POasFJuMGA,200000000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-6,200000000.0,duration,2022-04-08,2022-04-08,0001621227,http://www.sec.gov/CIK,duration_2022-04-08_2022-04-08,Aggregate offering price of ADS shares under At The Market sales agreement,Aggregate offering price of ADS shares under At The Market sales agreement,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,None,None,None,None,None,None,None,None,None,None,srt:MaximumMember,None,None,None,None,adap:SalesAgreement2022Member,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues_Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_-FU_prSANkK7X2g_T0pPLg,adap:StockSoldDuringPeriodRepresentedByAmericanDepositarySharesNewIssues,Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_-FU_prSANkK7X2g_T0pPLg,92416,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,92416.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Sold shares represented by American Depositary Shares (in shares),Sold shares represented by American Depositary Shares (in shares),Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_StockIssuedDuringPeriodSharesNewIssues_Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_-FU_prSANkK7X2g_T0pPLg,us-gaap:StockIssuedDuringPeriodSharesNewIssues,Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_-FU_prSANkK7X2g_T0pPLg,554496,Unit_Standard_shares_B6jprNB0-kuBkSPgy7QDDA,INF,554496.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,"Issuance of shares upon completion of public offering, net of issuance costs (in shares)","Issuance of shares upon completion of public offering, net of issuance costs (in shares)",StatementOfEquity,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfChangeInEquity,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ProceedsFromIssuanceOrSaleOfEquity_Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_-FU_prSANkK7X2g_T0pPLg,us-gaap:ProceedsFromIssuanceOrSaleOfEquity,Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_-FU_prSANkK7X2g_T0pPLg,173430,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,173430.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Net proceeds,Net proceeds,Disclosures,http://www.adaptimmune.com/role/DisclosureRevenueCollaborationAgreementGenentechCollaborationAndLicenseAgreementDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_StockIssuedSalesAgreementRemainingAmountAvailableForSale_Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_-FU_prSANkK7X2g_T0pPLg,adap:StockIssuedSalesAgreementRemainingAmountAvailableForSale,Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_adap_SalesAgreement2022Member_-FU_prSANkK7X2g_T0pPLg,186513100,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,0,186513100.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Remaining amount under the Sales Agreement,Remaining amount under the Sales Agreement,Disclosures,http://www.adaptimmune.com/role/DisclosureStockholdersEquityOfferingsDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,adap:SalesAgreement2022Member,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Note 14 – Restructuring</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On November 8, 2022, the Company announced that in order to extend the Company’s cash runway from early 2024 into early 2025, it was re-focusing the business on core programs and deprioritizing non-core programs and undertaking a restructuring of the Company including a headcount reduction to be completed in the first quarter of 2023.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The redundancy process was completed in the first quarter of 2023 with a reduction of approximately 25% of global headcount. The redundancy packages to be paid to departing staff comprise a combination of contractual termination benefits, relating to payments that arise from terms of employment contracts and statutory redundancy pay, and one-time employee termination benefits that were provided or enhanced specifically for this redundancy process. Due to the structure of the redundancy scheme and the different employment regulations affecting the Company’s U.K. and U.S. employees, some of the expense associated with the one-time employee termination benefits were recognized over the remaining period of employee service to be rendered. Contractual termination benefits and other one-time employee termination benefits were expensed and recognized in the year ended December 31, 2022. All expenses have been recognized in General and administrative expenses in the Statement of Operations.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The amounts incurred in relation to the redundancy programme are as follows:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">One-time</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Contractual</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">employee</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">termination</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">termination</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">restructuring</b></p></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">costs</b></p></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Cumulative amount incurred to December 31, 2022</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 1,171</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 1,114</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 2,285</p></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Amount incurred in the three months ended March 31, 2023</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 778</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 925</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 1,703</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total amount expected to be incurred and cumulative amount incurred to March 31, 2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,949</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,039</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,988</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The table below is a summary of the changes in the restructuring provision in the consolidated balance sheets in the three months ended March 31, 2023:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">One-time</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Contractual</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">employee</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">termination</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">termination</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">restructuring</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">provision</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Provision at January 1, 2023</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,171</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,114</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,285</p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Costs incurred and charged to General and administrative expenses</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 670</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 947</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,617</p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Costs paid during the period</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,955)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,953)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,908)</p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Adjustments to the liability</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 108</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (22)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 86</p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Effect of foreign exchange rates</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8</p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Provision at March 31, 2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 88</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 88</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""white-space:pre-wrap;"">The costs incurred during the period includes the element of one-time employee termination benefits that was recognized over the remaining period of employee service. The costs incurred during the period also include an addition to the provision for costs incurred  relating to termination benefits paid to the former Chief Commercial Officer, who left employment with the Company in the first quarter of 2023. </span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">No impairment losses were recognised as a result of the restructuring.</p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Restructuring,Restructuring,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuring,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_RestructureHeadcountReductionPercentage_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,adap:RestructureHeadcountReductionPercentage,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0.25,Unit_Standard_pure_G-B0CQCQ80y-KyTejbicdg,2,0.25,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Percent of headcount reduction,Percent of headcount reduction,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_RestructuringAndRelatedCostsExpectToBeIncurredTableTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,adap:RestructuringAndRelatedCostsExpectToBeIncurredTableTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The amounts incurred in relation to the redundancy programme are as follows:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">One-time</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Contractual</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">employee</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">termination</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">termination</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">restructuring</b></p></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:8.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">costs</b></p></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Cumulative amount incurred to December 31, 2022</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 1,171</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 1,114</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 2,285</p></td></tr><tr><td style=""vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Amount incurred in the three months ended March 31, 2023</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 778</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 925</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""> 1,703</p></td></tr><tr><td style=""vertical-align:bottom;white-space:nowrap;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Total amount expected to be incurred and cumulative amount incurred to March 31, 2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""><b style=""font-weight:bold;""> 1,949</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""><b style=""font-weight:bold;""> 2,039</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:6.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;""><b style=""font-weight:bold;""> 3,988</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Schedule of amounts incurred in relation to the redundancy programme,Schedule of amounts incurred in relation to the redundancy programme,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_As_Of_12_31_2022_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_UR1KQYpte0qFBhg4qgkERA,us-gaap:RestructuringAndRelatedCostCostIncurredToDate1,As_Of_12_31_2022_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_UR1KQYpte0qFBhg4qgkERA,1171000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1171000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Restructuring and Related Cost, Cost Incurred to Date","Restructuring and Related Cost, Cost Incurred to Date",Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ContractTerminationMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_As_Of_12_31_2022_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_FbgNA4JauEaVLyzuJY7Lqw,us-gaap:RestructuringAndRelatedCostCostIncurredToDate1,As_Of_12_31_2022_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_FbgNA4JauEaVLyzuJY7Lqw,1114000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1114000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Restructuring and Related Cost, Cost Incurred to Date","Restructuring and Related Cost, Cost Incurred to Date",Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,us-gaap:RestructuringAndRelatedCostCostIncurredToDate1,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,2285000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,2285000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,"Restructuring and Related Cost, Cost Incurred to Date","Restructuring and Related Cost, Cost Incurred to Date",Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringDetails,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_As_Of_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_CyBgLfcAGkO7nQLC5ns-SQ,us-gaap:RestructuringAndRelatedCostCostIncurredToDate1,As_Of_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_CyBgLfcAGkO7nQLC5ns-SQ,778000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,778000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Restructuring and Related Cost, Cost Incurred to Date","Restructuring and Related Cost, Cost Incurred to Date",Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ContractTerminationMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_As_Of_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_BDf8ypa9q0OWyzXZjBgXEg,us-gaap:RestructuringAndRelatedCostCostIncurredToDate1,As_Of_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_BDf8ypa9q0OWyzXZjBgXEg,925000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,925000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Restructuring and Related Cost, Cost Incurred to Date","Restructuring and Related Cost, Cost Incurred to Date",Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:RestructuringAndRelatedCostCostIncurredToDate1,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,1703000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1703000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,"Restructuring and Related Cost, Cost Incurred to Date","Restructuring and Related Cost, Cost Incurred to Date",Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostExpectedCost1_As_Of_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_CyBgLfcAGkO7nQLC5ns-SQ,us-gaap:RestructuringAndRelatedCostExpectedCost1,As_Of_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_CyBgLfcAGkO7nQLC5ns-SQ,1949000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1949000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total amount expected to be incurred,Total amount expected to be incurred,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ContractTerminationMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostExpectedCost1_As_Of_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_BDf8ypa9q0OWyzXZjBgXEg,us-gaap:RestructuringAndRelatedCostExpectedCost1,As_Of_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_BDf8ypa9q0OWyzXZjBgXEg,2039000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,2039000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total amount expected to be incurred,Total amount expected to be incurred,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringAndRelatedCostExpectedCost1_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,us-gaap:RestructuringAndRelatedCostExpectedCost1,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,3988000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,3988000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Total amount expected to be incurred,Total amount expected to be incurred,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringDetails,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">The table below is a summary of the changes in the restructuring provision in the consolidated balance sheets in the three months ended March 31, 2023:</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><table style=""border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;""><tr style=""height:1pt;""><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;""><div style=""height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;""><div style=""bottom:0pt;position:absolute;width:100%;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:1pt;visibility:hidden;"">​</span></p></div></div></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">One-time</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Contractual</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">employee</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:11pt;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">Total</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">termination</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">termination</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">restructuring</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;""><b style=""font-weight:bold;"">    </b></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">benefits</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-size:8pt;font-weight:bold;visibility:hidden;"">​</span></p></td><td colspan=""2"" style=""vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;""><b style=""font-weight:bold;"">provision</b></p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Provision at January 1, 2023</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,171</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,114</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"">$</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2,285</p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Costs incurred and charged to General and administrative expenses</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 670</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 947</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 1,617</p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Costs paid during the period</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,955)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (1,953)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (3,908)</p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Adjustments to the liability</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 108</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""> (22)</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 86</p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"">Effect of foreign exchange rates</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 6</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 2</p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;""><span style=""visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""> 8</p></td></tr><tr><td style=""vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Provision at March 31, 2023</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> —</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 88</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""font-weight:bold;visibility:hidden;"">​</span></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">$</b></p></td><td style=""vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;""><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;""><b style=""font-weight:bold;""> 88</b></p></td></tr></table><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Schedule of changes in the restructuring provision,Schedule of changes in the restructuring provision,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringTables,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_12_31_2022_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_UR1KQYpte0qFBhg4qgkERA,us-gaap:RestructuringReserve,As_Of_12_31_2022_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_UR1KQYpte0qFBhg4qgkERA,1171000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1171000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ContractTerminationMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_12_31_2022_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_FbgNA4JauEaVLyzuJY7Lqw,us-gaap:RestructuringReserve,As_Of_12_31_2022_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_FbgNA4JauEaVLyzuJY7Lqw,1114000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1114000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw_0,us-gaap:RestructuringReserve,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,2285000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,2285000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw_1,us-gaap:RestructuringReserve,As_Of_12_31_2022_PowXFsb61EuNNNIjxMGgKw,2285000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,2285000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2022-12-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2022-12-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringCharges_Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_lUpyU39QWEu37C4H3g_1kw,us-gaap:RestructuringCharges,Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_lUpyU39QWEu37C4H3g_1kw,670000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,670000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Costs incurred and charged to General and administrative expenses,Costs incurred and charged to General and administrative expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ContractTerminationMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringCharges_Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_53ukVeSkvEqvuLWc07CCpA,us-gaap:RestructuringCharges,Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_53ukVeSkvEqvuLWc07CCpA,947000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,947000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Costs incurred and charged to General and administrative expenses,Costs incurred and charged to General and administrative expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringCharges_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:RestructuringCharges,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,1617000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1617000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Costs incurred and charged to General and administrative expenses,Costs incurred and charged to General and administrative expenses,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PaymentsForRestructuring_Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_lUpyU39QWEu37C4H3g_1kw,us-gaap:PaymentsForRestructuring,Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_lUpyU39QWEu37C4H3g_1kw,1955000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1955000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Costs paid during the period,Costs paid during the period,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ContractTerminationMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PaymentsForRestructuring_Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_53ukVeSkvEqvuLWc07CCpA,us-gaap:PaymentsForRestructuring,Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_53ukVeSkvEqvuLWc07CCpA,1953000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,1953000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Costs paid during the period,Costs paid during the period,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_PaymentsForRestructuring_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:PaymentsForRestructuring,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,3908000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,3908000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Costs paid during the period,Costs paid during the period,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveAccrualAdjustment1_Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_lUpyU39QWEu37C4H3g_1kw,us-gaap:RestructuringReserveAccrualAdjustment1,Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_lUpyU39QWEu37C4H3g_1kw,108000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,108000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Adjustments to the liability,Adjustments to the liability,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ContractTerminationMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveAccrualAdjustment1_Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_53ukVeSkvEqvuLWc07CCpA,us-gaap:RestructuringReserveAccrualAdjustment1,Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_53ukVeSkvEqvuLWc07CCpA,-22000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,-22000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Adjustments to the liability,Adjustments to the liability,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveAccrualAdjustment1_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:RestructuringReserveAccrualAdjustment1,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,86000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,86000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Adjustments to the liability,Adjustments to the liability,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveTranslationAdjustment_Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_lUpyU39QWEu37C4H3g_1kw,us-gaap:RestructuringReserveTranslationAdjustment,Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember_lUpyU39QWEu37C4H3g_1kw,6000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,6000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Effect of foreign exchange rates,Effect of foreign exchange rates,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:ContractTerminationMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveTranslationAdjustment_Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_53ukVeSkvEqvuLWc07CCpA,us-gaap:RestructuringReserveTranslationAdjustment,Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_53ukVeSkvEqvuLWc07CCpA,2000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,2000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Effect of foreign exchange rates,Effect of foreign exchange rates,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserveTranslationAdjustment_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:RestructuringReserveTranslationAdjustment,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,8000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,8000.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Effect of foreign exchange rates,Effect of foreign exchange rates,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_BDf8ypa9q0OWyzXZjBgXEg,us-gaap:RestructuringReserve,As_Of_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OneTimeTerminationBenefitsMember_BDf8ypa9q0OWyzXZjBgXEg,88000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,88000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,us-gaap:OneTimeTerminationBenefitsMember,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_0,us-gaap:RestructuringReserve,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,88000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,88000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_RestructuringReserve_As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA_1,us-gaap:RestructuringReserve,As_Of_3_31_2023_zQOS3-e7L0G-yMv9bsnaJA,88000,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,88000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-03-31,Restructuring provision,Restructuring provision,BalanceSheet,http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets,2023-03-31,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_ImpairmentLossOnRestructuring_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,adap:ImpairmentLossOnRestructuring,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,0,Unit_Standard_USD_pGmLTiZrlECI_yEr9usNnQ,-3,0.0,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Impairment loss,Impairment loss,Disclosures,http://www.adaptimmune.com/role/DisclosureRestructuringMovementsInProvisionDetails,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
us-gaap_SubsequentEventsTextBlock_Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,us-gaap:SubsequentEventsTextBlock,Duration_1_1_2023_To_3_31_2023_p53OJpk2DEWPUTBMlelTIQ,"<p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><b style=""font-weight:bold;"">Note 15 – Subsequent events</b></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">GSK Termination and Transfer Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On April 11, 2023, the Company announced the entry of the Company and GSK into a Termination and Transfer Agreement (the “Termination and Transfer Agreement” as per Note 3) regarding the return of rights and materials comprised within the PRAME and NY-ESO cell therapy programs. The parties will work collaboratively to ensure continuity for patients in ongoing lete-cel clinical trials forming part of the NY-ESO cell therapy program. In addition, under the Termination and Transfer Agreement, Adaptimmune will receive an upfront amount and milestone payments totaling £30 million in relation to the transfer of the clinical trials for the NY-ESO cell therapy program.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""display:inline-block;text-indent:0pt;width:36pt;""/><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"">TCR</i><sup style=""font-size:7.5pt;font-style:italic;line-height:100%;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;top:0pt;vertical-align:top;"">2</sup><i style=""font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;""> Therapeutics Inc. Merger Agreement</i></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">On March 6, 2023 the Company announced entry into a definitive agreement under which it will combine with TCR² Therapeutics Inc. (TCR²) in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors. The transaction is expected to close in Q2 2023, subject to the receipt of approvals by Adaptimmune shareholders and TCR<sup style=""font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"">2</sup><span style=""white-space:pre-wrap;""> stockholders and satisfaction or waiver of other closing conditions.  Following the closing of the transaction we currently estimate that the cash runway of the combined company will extend into early 2026.  In the event that the transaction does not close we currently estimate that our cash runway would extend into early 2025.</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"">As the transaction is not expected to close until Q2 2023, an estimate of the other financial effects of this event on the Company cannot yet be made.</p><p style=""font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;""><span style=""visibility:hidden;"">​</span></p>",None,None,,duration,2023-01-01,2023-03-31,0001621227,http://www.sec.gov/CIK,duration_2023-01-01_2023-03-31,Subsequent events,Subsequent events,Disclosures,http://www.adaptimmune.com/role/DisclosureSubsequentEvents,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,None,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
adap_UpfrontAndMilestonePaymentReceivable_As_Of_4_11_2023_srt_CounterpartyNameAxis_adap_GlaxosmithklineIntellectualPropertyDevelopmentLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_adap_TerminationAndTransferAgreementMember_vH_kDT-D20-HU7HN-Ltwfg,adap:UpfrontAndMilestonePaymentReceivable,As_Of_4_11_2023_srt_CounterpartyNameAxis_adap_GlaxosmithklineIntellectualPropertyDevelopmentLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_adap_TerminationAndTransferAgreementMember_vH_kDT-D20-HU7HN-Ltwfg,30000000,Unit_Standard_GBP_N4t8JZSo0kOxdF5S7hTHRQ,-6,30000000.0,instant,None,None,0001621227,http://www.sec.gov/CIK,instant_2023-04-11,Upfront and milestone payment receivable,Upfront and milestone payment receivable,Disclosures,http://www.adaptimmune.com/role/DisclosureSubsequentEventsDetails,2023-04-11,None,None,None,None,adap:TerminationAndTransferAgreementMember,None,None,None,None,None,None,adap:GlaxosmithklineIntellectualPropertyDevelopmentLtdMember,None,None,None,None,us-gaap:SubsequentEventMember,ADAP,2023-05-12,Q2,2023,Adaptimmune Therapeutics PLC
